**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 47858

**Manuscript Type:** REVIEW

**Intestinal enteroids/organoids: a novel platform for drug discovery in inflammatory bowel diseases**

Yoo JH *et al*. Intestinal enteroids/organoids and IBD drug discovery

Jun-Hwan Yoo, Mark Donowitz

**Jun-Hwan Yoo, Mark Donowitz,** Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States

**Jun-Hwan Yoo,** Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam 13496, South Korea

**ORCID number:** Jun-Hwan Yoo (0000-0002-5810-4019); Mark Donowitz (0000-0003-0477-8824).

**Author contributions:** Yoo JH and Donowitz M have substantial contributions to conception and design of the review, and literature review; Yoo JH drafted and edited the article; Donowitz M revised the manuscript critically for important intellectual content; Yoo JH and Donowitz M worked together for the final approval of the version to be published.

**Supported by** Basic Science Research Program through the National Research Foundation of Korea, No. 2015R1C1A1A02037048; and National Research Foundation of Korea, No. 2019R1H1A1035601.

**Conflict-of-interest statement:** Nopotential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Jun-Hwan Yoo, MD, PhD,** **Assistant Professor,** Digestive Disease Center, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam 13496, South Korea. jhyoo@cha.ac.kr

**Telephone:** +82-31-8817180

**Fax:** +82-31-7805219

**Received:** March 27, 2019

**Peer-review started:** March 28, 2019

**First decision:** May 30, 2019

**Revised:** June 14, 2019

**Accepted:** July 19, 2019

**Article in press:** July 19, 2019

**Published online:** August 14, 2019

**Abstract**

The introduction of biologics such as anti-tumor necrosis factor (TNF) monoclonal antibodies followed by anti-integrins has dramatically changed the therapeutic paradigm of inflammatory bowel diseases (IBD). Furthermore, a newly developed anti-p40 subunit of interleukin (IL)-12 and IL-23 (ustekinumab) has been recently approved in the United States for patients with moderate to severe Crohn’s disease who have failed treatment with anti-TNFs. However, these immunosuppressive therapeutics which focus on anti-inflammatory mechanisms or immune cells still fail to achieve long-term remission in a significant percentage of patients. This strongly underlines the need to identify novel treatment targets beyond immune suppression to treat IBD. Recent studies have revealed the critical role of intestinal epithelial cells (IECs) in the pathogenesis of IBD. Physical, biochemical and immunologic driven barrier dysfunctions of epithelial cells contribute to the development of IBD. In addition, the recent establishment of adult stem cell-derived intestinal enteroid/organoid culture technology has allowed an exciting opportunity to study human IECs comprising all normal epithelial cells. This long-term epithelial culture model can be generated from endoscopic biopsies or surgical resections and recapitulates the tissue of origin, representing a promising platform for novel drug discovery in IBD. This review describes the advantages of intestinal enteroids/organoids as a research tool for intestinal diseases, introduces studies with these models in IBD, and gives a description of the current status of therapeutic approaches in IBD. Finally, we provide an overview of the current endeavors to identify a novel drug target for IBD therapy based on studies with human enteroids/organoids and describe the challenges in using enteroids/organoids as an IBD model.

**Key words:** Enteroids; Organoids; Inflammatory bowel diseases; Crohn’s disease; Ulcerative colitis

**© The Author(s) 2019** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Although intestinal epithelial cells are regarded as crucial regulators of barrier function in the pathogenesis of inflammatory bowel diseases (IBD), the development of novel IBD drugs targeting intestinal barrier dysfunction has been hampered by the lack of long-term human intestinal epithelial cultures. Novel intestinal enteroids/organoids derived from adult intestinal stem cells, are expected to play an important role in developing novel drugs for diverse intestinal diseases. The main purpose of this review is to provide the current status of therapeutic approaches in IBD and to highlight the potential to use human enteroids/organoids as a platform to develop novel drugs for IBD.

Yoo JH, Donowitz M. Intestinal enteroids/organoids: a novel platform for drug discovery in inflammatory bowel diseases. *World J Gastroenterol* 2019; 25(30): 4125-4147

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i30/4125.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i30.4125

**INTRODUCTION**

Inflammatory bowel diseases (IBD) are chronic relapsing-remitting disorders with unknown etiology comprising Crohn’s disease (CD) and ulcerative colitis (UC). IBD has been thought to result from a dysregulated, inappropriate immune response to commensal microbes in a genetically susceptible host with environmental factors (dietary factors, smoking, drugs, *etc.*) contributing to the disease risk[1,2].

Over the last decades, anti-tumor necrosis factor (TNF) monoclonal antibodies as well as long relied upon conventional therapies (5-Aminosalicylates, corticosteroids, immunosuppressive agents) have been used to induce remission by targeting immune cells or inflammatory mechanisms. Recently developed biologics (anti-integrins, anti-p40 subunit of IL-12 and IL-23) also act through immunomodulation. These agents have dramatically contributed to increase the rate of clinical remission. Despite advances of biologics, currently, one-third of patients with CD and one sixth of patients with UC require surgery within 5 years after diagnosis[3-8]. This suggests that current anti-inflammatory or immune suppressive strategy is not enough to overcome the heterogeneous, multifactorial IBD. Therefore, new therapeutic strategy targeting other types of cells or mechanisms are needed.

Growing evidence suggests that intestinal epithelial cell (IEC) dysfunction plays a major role in the pathogenesis and perpetuation of IBD[1,9]. Several genetic alterations of IBD are associated with epithelial functions including integrity maintenance (*PTPN2*, *CDH1, PTGER4*), secretory defense (*XBP1*, *ATG16L1*), and bacterial sensing (*CARD15*)[9-12]. Mucosal healing achieved by regeneration of IECs is associated with more favorable prognoses in IBD such as decreased relapse, low risk of admission and surgery, and long-term clinical remission[1,9,13]. Several studies have shown that intestinal epithelium of IBD can harbor persistent alterations in gene expression or DNA methylation despite complete endoscopic and histologic remission, which could contribute to disease relapse or perpetuation[9,14-17]. However, no drugs directly targeting changes in IECs in IBD have been developed. This might be attributed to the inability to maintain long-term primary IEC cultures as well as to the previous drug development based on immortalized cell lines or animal models which are mechanistically different from human IBD[18-20].

Recently, remarkable progress has been made in long-term primary IEC cultures called human intestinal enteroids (small intestine) and colonoids (colon)/organoids which develop from human adult intestinal stem cells (ISCs)[21-23]. Ex vivo human enteroid/organoid cultures have diverse advantages over traditional animal models and cell lines in context of recapitulating human in vivo physiology, even after many generations, apparently with limited genetic or physiologic alterations[24]. Additionally, intestinal enteroids/organoids can be easily established from endoscopic biopsies in IBD patients and maintain the location or some disease specific features[14,25-28]. Therefore, the intestinal enteroid/organoid culture system represents a promising tool for IBD modeling and drug development focusing on IEC dysfunction. However, the current limitation of this model is that it is not yet known if this model maintains the inflammatory phenotype and epigenetic stem cell modifications that occur in the IBDs.

**Intestinal enteroids/organoids derived from adult ISCs**

Human “mini-intestines” are derived either from adult ISCs (enteroids/organoids)[23,29] or from induced pluripotent stem cells (iPSCs)(organoids)[30]. The iPSCs-derived intestinal organoids contain both epithelium and mesenchyme including myofibroblasts, smooth muscle cells[29-31] but have limitations of requiring meticulous maintenance and initially mimicking fetal tissue. In contrast, the adult ISCs-derived intestinal enteroids/organoids can be easily established from human tissue (intestinal crypts), making it a tool more accessible to general researchers[29]. Thus, this review specifically focuses on intestinal enteroids/organoids derived from an adult ISC origin.

Intestinal enteroids/organoids can be generated from single Lgr5+ (Leucine-rich repeat-containing G protein-coupled receptor 5) ISC plus Paneth cells or from intestinal crypts containing ISCs[21-23]. Intestinal crypts can be isolated from surgical resections or endoscopic biopsies, embedded in Matrigel (an extracellular matrix-containing substance), and cultured as three-dimensional (3D) spheroids in several growth factors (Wnt3A, R-spondin, Noggin, and EGF) enriched media[32]. After withdrawal of critical growth factors, intestinal enteroids/organoids differentiate to mimic IECs in villi composed of mature enterocytes, enteroendocrine cells, goblet cells, and tuft cells while ISCs and transit-amplifying cells are lost[32].

**The advantages of intestinal enteroids/organoids as a research tool for intestinal diseases**

Intestinal enteroid/organoid culture system can overcome the limitations of immortalized epithelial cell lines, human fetal intestinal organ cultures, and animal models. In contrast to cell lines which are genetically transformed and thus represent altered genotypes and phenotypes significantly different from those of primary cells[19], the intestinal enteroid/organoid culture is a primary culture system which maintains in vivo characteristics of human intestinal epithelium even after many passages[21]. Furthermore, the current human cancer derived intestinal epithelial cell lines, as normally grown, consist of a single cell type (*e.g.,* Caco-2, HT29: enterocyte[33,34]) and thus fail to recapitulate the diversity of cell types in the normal intestinal epithelium. In contrast, intestinal enteroids/organoids can give rise to all the types of epithelial cells in crypt or villus structure (ISCs, Paneth cells, transit amplifying cells, enteroendocrine cells, goblet cells, enterocytes, tuft cells, and microfold cells)[21,35-37]. Thus, intestinal enteroids/organoids can more closely reflect normal physiology or disease pathogenesis of intestinal epithelium where each single type of IECs interact with other types of IECs by paracrine and autocrine mechanisms[38].

Human fetal intestinal organ culture, which is prepared from intestinal tissue obtained from therapeutic abortions, has been used to study the fetal intestinal immune response to luminal microbes[39] and the pathogenesis of necrotizing enterocolitis[40] and celiac disease[41]. Human fetal intestinal organ culture has a strength of providing multiple cell types and sequential differentiation which are not preserved in intestinal enteroid/organoid cultures. However, in comparison to enteroids/organoids, intestinal human fetal intestinal organ culture has several weaknesses. These include the application of high throughput drug screening, difficulty in obtaining fetal tissue, short viability (up to 48h), limitation in delivery of exogenous stimuli and real-time monitoring due to the thickness of the intestinal tissue[42].

In the drug development process, animal models have provided a wide range of systemic response, however, these models are resource-intensive (cost, time, labor) and low-throughput[43]. More importantly, the mechanistic differences between animal models and human diseases might be one of the critical factors contributing to drug failure in clinical trials[38]. Meanwhile, intestinal enteroids/organoids-based drug screening can be high throughput by an in vitro culture system, mechanistically similar to human diseases, and thus potentially more precisely predicting drug response in humans. In particular, growing enteroids as polarized monolayers instead of spheroids allows direct apical and basolateral access by pathogens and oral drugs, and subsequently enables the effective study of ion transport and secretory functions. A recent study demonstrated the successful use of enteroid monolayers in drug discovery by miniaturizing mouse colonoid monolayer cultures to 96-well plates, and conducting a phenotypic screen of approximately 2,000 drug candidates[44]. We have adopted the following approach for development of anti-diarrheal drugs. Identification of drug targets includes studies in diarrheal models in human enteroid monolayers. Initial drug candidates are screened early for toxicity in human enteroids with further development curtailed if human intestinal toxicity is identified. Once pharmacokinetic approaches are carried out in mouse intestine and human colon cancer cell lines, human enteroids are studied to determine IC50 and if similar it is considered that the specific drug can be further developed. This approach was used with the CFTR inhibitor BPO-27 which is now under development by pharma for phase I and II studies[45].

Human enteroids are amenable to lipofectamine-, low voltage electroporation-, and viral-based genetic manipulation including knock down, knock-out, knock-in, or overexpression[38]. The CRISPR/Cas9 system was also used to edit the genome of intestinal enteroids derived from cystic fibrosis patients and repaired the cystic fibrosis transmembrane conductance regulator (CFTR) function[46].

The indefinitely propagating intestinal enteroid/organoid cultures can be very useful to investigate long-term pathogenesis of intestinal diseases such as chronic inflammation, fibrosis and colitis associated cancer (CAC)[47,48]. In contrast to iPSCs-derived intestinal organoids which can acquire genetic and epigenetic variations during culturing[49] or isolated primary IECs which rapidly enter into anoikis (detachment induced apoptosis), ISCs-derived intestinal enteroids/organoids appear to be genetically, epigenetically, and phenotypically stable during long-term culture[9,21,46,50], although more detailed characterization is needed.

Intestinal enteroids/organoids faithfully retain the physiological and pathological features from intestinal segment of origin[25,27]. Previous studies showed that intestinal enteroids/organoids retain the tissue specific (region-specific, age-specific, and disease-specific) transcriptional and epigenetic profiles which might be programmed within ISCs. The long-term cultures of both human and mouse intestinal enteroids/organoids demonstrated that region-specific gene expression (duodenum/jejunum/ileum) is intrinsically imprinted in ISCs, for example, *Gata4* in duodenum and jejunum suppresses expression of ileal genes, and that their differentiation fate is independent of region-specific extracellular signals[25]. Another study identified gut-segment specific DNA methylation patterns in human intestinal enteroids/organoids derived from small and large bowel[26]. The DNA methylation patterns were cellular environment-independent and retained in intestinal enteroids/organoids over long-term culture. Interestingly, fetal gut-derived intestinal enteroids/organoids showed marked dynamic changes of DNA methylation and gene expression indicating in vitro maturation. This result suggests that intestinal enteroids/organoids can retain age or development-specific signatures in ISCs[26]. Compared with non-IBD subjects, intestinal enteroids/organoids generated from UC patients showed different gene expression profiles (genes associated with antimicrobial defense, secretory and absorptive functions) which are possibly due to permanent changes in ISCs[14]. Moreover, ISCs derived from active CD patients revealed a distinct gene expression pattern of ISC markers (LGR5 and SMOC2)[27]. In a recent study, Howell et al. identified that IECs from children with CD or UC showed specific changes in DNA methylation and transcription which were stable over time and were partly retained in intestinal enteroid/organoid cultures[28]. Table 1 compares the transcriptional or epigenetic features of intestinal enteroids/organoids derived from each intestinal segment or from normal or diseased intestine.

**Epithelial barrier dysfunctions: a pressing need for intestinal enteroids/organoids-based IBD research**

IBD is known to develop from an uncontrolled host immune response to commensal bacteria, with genetic susceptibility and environmental factors[2]. In addition, emerging evidence has revealed the role of IECs as regulators of mucosal immune homeostasis and highlighted the importance of the epithelial barrier function in pathophysiology of IBD, further supporting a pressing need for intestinal enteroids/organoids-based IBD research[1,51]. Intestinal epithelium apically contacts with luminal microbial flora and environmental factors, and basolaterally interacts with lamina propria immune cells. Moreover, several susceptibility genes of IBD are associated with epithelial innate immune functions and barrier functions[2,12]. Thus, IECs are located at the crossroad linking major IBD risk factors. Diverse barrier dysfunctions of IECs which play a key role in IBD pathogenesis are identified as follows.

***Physical barrier dysfunction of IECs***

As a physical barrier, IECs form a semi-permeable lining and segregate luminal microbial flora from host immune system to prevent infection or inflammation. IECs maintain physical barrier function by tight junctions (TJs), adherens junctions (AJs), and desmosomes which connect adjacent IECs and regulate intestinal permeability. In IBD, pro-inflammatory cytokines (*e.g.,* TNF-α, IFN-γ) disrupt TJs and increase permeability by cytoskeletal reorganization of IECs[11]. Also, polymorphisms in several IBD susceptibility genes which regulate expression and assembly of TJs and AJs, result in downregulation of junctional proteins leading to increased permeability, facilitating exposure of luminal bacteria and antigens to the host immune system[12]. To maintain the continuity of epithelial barrier after tissue injury, the voids created during the extrusion of either apoptotic or necrotic cells are rapidly covered by adjacent cells (termed restitution), followed by more delayed process of wound healing including the reinforcement of freshly developed IECs which are continuously differentiated and proliferated from ISCs[52]. Trefoil factors (TFFs), which are secreted from goblet cells, are known to be the initiators of mucosal healing by promoting restitution and by suppressing IEC apoptosis[53]. Down regulated TFFs in goblet cells have been implicated in the pathogenesis of IBD[54-56] (Figure 1A).

***Biochemical barrier dysfunction of IECs***

Furthermore, as a biochemical barrier, IECs secrete several anti-microbial peptides, secretory IgA and mucin2 (MUC2). Thick mucus layer act as a chemical boundary, preventing pathogenic bacterial invasion by trapping microbes with its viscosity[51]. In active UC, mucus layer is thinner and *MUC2* expression is reduced by goblet cell depletion[57]. Recent studies showed the down-regulation of bicarbonate transporter (BEST2, bestrophin2) expression in goblet cells of UC patients[58,59], which is associated with mucus dysfunction and UC pathogenesis. Anti-microbial peptides secreted from Paneth cells (defensins, cathelicidins, lysozyme) or enterocytes (REGIIIγ, regenerating islet-derived protein IIIγ) maintain host immunity by formation of micropores in the bacterial membrane which break bacterial integrity[11,51]. However, in IBD, several genetic defects in autophagy and the unfolded protein response (UPR) result in endoplasmic reticulum (ER) stress and apoptosis, which induce secretory dysfunctions of Paneth cells and goblet cells[11,60-63] (Figure 1B). In particular, Paneth cell secretory dysfunction has been implicated in the pathogenesis of ileal CD[60,61,63,64] and the expression of Paneth cell α-defensin has been shown to be decreased in patients with ileal CD[65]. Several genetic susceptibility factors of CD have been linked to Paneth cell dysfunction. These susceptibility factors encode proteins which are associated with pathogen recognition (NOD2)[66], ER stress (XBP1, X-box-binding protein 1), autophagy (ATG16L1, Autophagy-related16 like 1[62]), and defensin production (TCF4, T cell-specific transcription factor 4)[60,61,63,65].

***Innate immune dysfunction of IECs***

As an immune homeostasis regulator, IECs have well evolved and diverse functions, such as microbial recognition, sampling and transcellular transport of luminal contents (microfold cell), and regulated innate and adaptive immune cell functions[11,51]. In normal physiology, IECs recognize commensal bacteria with pattern recognition receptors (PRR: Toll-like receptor, TLR, NOD-like receptor, NLR) and maintain the mononuclear phagocytes in a tolerogenic phenotype by hyporesponsive PRR signaling[67,68]. Under active IBD conditions, TLR4 expression is significantly upregulated in IECs in both CD and UC, which compromise the hyporesponsiveness of IECs and amplify inappropriate immune response[69,70]. NOD2 polymorphisms in IECs are well known to be associated with an impaired intracellular microbial recognition and consequent long lasting nuclear factor kappa B (NF-kB) activation, which leads to the inflammation in CD[71,72]. Recent studies also revealed that normal IECs act as non-professional antigen presenting cells preferentially activating CD8+ regulatory T cells which result in a suppressed immune response. This occurs through a combination of the non-classical MHC class I molecule, CD1d and the costimulatory molecule glycoprotein gp-180 (CD8 ligand)[73-75] (Figure 1C). In contrast, the amount of CD8+ regulatory T cells was significantly decreased in IBD patients, which might be due to the defective expression of gp-180 on IECs[76]. Furthermore, IECs from IBD patients preferentially activate CD4+ T cell to proliferate and secrete IFN-γ[73].

**Current status of therapeutic approaches in IBD**

Although IBD is a spectrum of complex multifactorial disorders and recent studies have unraveled some aspects of the critical role of intestinal epithelial dysfunction in the pathogenesis of IBD, current therapeutic strategies and targets are mainly focused on suppression of immune cell (T cell) activation, proliferation, pro-inflammatory cytokine gene expression, migration/trafficking, and resistance to apoptosis[77]. Meanwhile, several drugs or therapies have been reported to promote epithelial barrier functions such as mucin production or integrity maintenance. However, only a few therapies specifically and directly target the barrier dysfunction of IECs. Thus, there is still a large unmet need for novel IBD drug discovery which potentially could be achieved based on the intestinal enteroid/organoid-culture system.

***Current therapeutic approaches in IBD focused on immune cells***

The Majority of current or emerging IBD therapies, at least in part, are based on suppression of pro-inflammatory cells or pathways. Classical anti-inflammatory drugs (5-Aminosalicylate, corticosteroid) inhibit pro-inflammatory cytokine production in immune cells by NF-kB inactivation[77,78]. Classical immunosuppressive agents also act through similar mechanisms. Azathioprine and 6-mercaptopurine are metabolized to suppress small GTPase RAC1, leading to inactivation and apoptosis of CD4+ T cells[79]. Cyclosporine-A and tacrolimus treatment modulate pro-inflammatory cytokine transcription and T cell survival in UC by blocking calcineurin and inducing apoptosis[80,81]. Moreover, methotrexate has a pro-apoptotic effect on proliferating CD4+ T cells with poly (ADP-ribose) polymerase (PARP)-dependent pathway[82].

Several current or emerging biologic therapies are based on blockade of pro-inflammatory cytokines produced by various immune cells. Anti-TNF agents (infliximab, adalimumab, golimumab, and certolizumab pegol) specifically neutralize TNF and are effective in both induction and maintenance of remission in UC and CD[83]. Furthermore, the combination therapy of azathioprine and an anti-TNF agent has dramatically reduced the need to use corticosteroids for IBD treatment[84]. However, only 30-50% of patients achieve clinical and mucosal remission and significant number of initial responders experience loss of response due to antibody formation or increased drug clearance rates[85]. Recently approved ustekinumab (antibody against IL-12/IL-23 p40 subunit[86]) for CD therapy effectively suppress type 1 and type 17 T helper (Th1, Th17) cell responses which are increased in CD or UC. Approximately 30% of moderate to severe CD patients who failed to respond to anti-TNFs achieved clinical remission when they were treated with ustekinumab for 6 weeks, but half of initial responders lost response at week 44[5]. IL-6 has multiple pro-inflammatory effects including inhibition of apoptosis in mucosal T-cells and is a logical target for treating CD. IL-6 can bind to cells lacking the membrane-bound IL-6 receptor (IL-6R) by forming a complex with the soluble IL-6R, and subsequently induce anti-apoptotic response *via* IL-6/STAT3 pathway[87]. Recently, a novel anti-IL-6 antibody (PF-04236921) induced significantly higher clinical responses and remissions in refractory patients with moderate-to-severe CD following anti-TNF therapy. The overall benefit/risk profile for this drug appears to be acceptable but the observations of gastrointestinal perforation and abscess require careful consideration during future clinical development[88]. IL-6R blockade was also effective in suppressing inflammatory activity in CD. A phase 1 trial using an anti-IL-6R monoclonal antibody (tocilizumab, previously known as MRA) showed higher response and remission rates in CD patients as compared with the placebo group[89].

Moreover, there are new small molecules which inhibit intracellular pro-inflammatory pathways targeting cytokine signaling or transcription factors. Several Janus kinase inhibitors (JAK inhibitors: tofacitinib, filgotinib) block intracellular activation of Janus kinases which mediate cytokine signaling with respect to proliferation, survival, activation in immune cells. Patients with active UC treated with tofacitinib (JAK1/2/3 inhibitor) were more likely to have clinical response and remission than those receiving placebo in a phase II trial[90]. In vitro, tofacitinib inhibited IL-12-dependent Th1 differentiation, IL-4-dependent Th2 differentiation, and also impaired the differentiation of Th17 cells in response to IL-1β, IL-6, and IL-23[91]. Additionally, a novel ROR-γt (RAR-related orphan receptor-γt) inhibitor transiently and selectively reduced Th17 cell differentiation and cytokine production from Th17 cells but preserved group 3 innate lymphoid cells (ILC3s) which provide tissue protection in the intestine[92]. GATA3 is a transcription factor which is increased in UC patients and induces pro-inflammatory cytokines in T cells. Rectal delivery of GATA3-specific DNAzyme inhibited GATA3, and subsequently reduced Th2 cytokine (IL-6, IL-13) production in lamina propria mononuclear cells in mouse colitis[93].

Rather than targeting cytokines and immune cells which are already present in inflamed sites as above, other drugs inhibit trafficking or homing of activated T cells toward the inflamed gut. Several Integrin inhibitors (anti-α4β7 vedolizumab, anti-β7 etrolizumab) have already shown their clinical efficacies in IBD therapy[6-8,94,95]. Moreover, a recent study developed a small molecule inhibitor of chemokine receptor CCR9 (CCX282-B) which is expressed in leukocyte and plays a key role for leukocyte homing to the gut mucosa[96,97]. Meanwhile, other groups are targeting adhesion molecules which are expressed in vascular endothelial cells. A novel MAdCAM-1 (gut specific ligand for integrin α4β7) antibody increased β7+ T cells and CCR9 gene expression in the peripheral blood of patients with CD in a phase 2 trial, which indicates that anti-MAdCAM-1 antibody successfully can prevent the influx of immune cells into the gut[98,99]. Alicaforsen is a human ICAM-1 antisense oligonucleotide which inhibits ICAM-1 production in vascular endothelial cells, and thereby blocks leukocyte trafficking to the mucosa[100]. Another approach regarding immune cell trafficking in IBD involves sphingosine-1-phosphate (S1P) signaling. S1P/S1P receptor signaling controls the egress of lymphocytes from lymph nodes to circulation by activating NF-kB and STAT3 transcription factors. The S1P receptor agonist/functional antagonist (ozanimod), which sequesters peripheral lymphocytes, resulted in a higher clinical remission rate in UC[101-103].

Finally, several emerging IBD therapies focus on activation of anti-inflammatory mechanisms rather than inhibition of pro-inflammatory mechanisms. Normally, anti-inflammatory TGFβ/SMAD3 signaling downregulates NF-kB transcription. Under IBD conditions, SMAD7 proteins are upregulated, and thereby inhibit TGFβ/SMAD3 signaling, leading to uncontrolled inflammation. The novel anti-SMAD7 oligonucleotide (Mongersen) interferes with this inhibitory process by degradation of the SMAD7 mRNA. It subsequently resulted in significantly higher rates of clinical remission in CD patients[104]. Moreover, mesenchymal stem cells (MSCs) have been known to exert potent immunomodulatory functions on antigen specific T cells in CD patients through paracrine and cell-to-cell contact mechanisms[105]. Subsequently, various clinical trials have already shown anti-inflammatory and fistula closure effects of the MSCs in fistulizing CD patients[77,106]. In addition, T cell transplantation (regulatory T cells) in refractory CD patients, was well tolerated and induced significant reduction in the Crohn’s disease activity index[107]. Table 2 summarizes current therapeutic approaches in IBD focused on immune cells.

***Current therapeutic approaches in IBD focused on IECs***

A few studies have reported several drug candidates which might be helpful to correct the physical barrier dysfunction of IECs by promoting epithelial cell proliferation or TJ assembly. IL-22 is known to promote epithelial cell proliferation by acting directly on ISCs through STAT3 activation[108-110]. T cells isolated from patients with IBD produce high levels of IL-22 binding protein (IL-22BP), which inhibits IL-22. A recent study showed that the mucosal healing effect of anti-TNFα therapy may act in part by blocking IL-22BP[111]. Also, oral tauroursodeoxycholate (TUDCA) restores ER function by improving UPR and ameliorates colitis in mice[112]. Epidermal growth factor (EGF) is indispensable for proliferation of ISCs and is used as an important growth factor in intestinal enteroid/organoid cultures[21,113]. A preliminary study suggested that EGF enemas are an effective treatment for active left-sided UC[114]. The modulation of TJs can also be a promising target by increasing epithelial integrity. An octapeptide (AT-1001), which inhibits the disassembly of TJs by interfering with cytoskeletal rearrangement, appeared to reduce epithelial barrier dysfunction in celiac disease[115]. Celiac disease shares some common immune pathogenesis with IBD, including a dysregulated intestinal epithelial permeability[116], which suggests that AT-1001 might be considered as a novel IBD drug. Moreover, several existing drugs (vitamin D, estradiol, and metformin) also have shown to reduce epithelial permeability and to alleviate mucosal inflammation in IBD mouse models[117-119].

There have been other approaches to correct the biochemical dysfunctions or innate immune dysfunctions of IECs. However, most of them focus on mucus dysfunction of IECs. Several therapeutic approaches such as prostaglandin E2 (PGE2) receptor EP4 agonist, butyrate (short chain fatty acid), and cathelicidin have shown to induce mucus production in IECs as well as to reduce colitis in mice[120-124]. A novel mucin component therapy (phosphatidylcholine) has shown to produce a significant improvement in disease activity in UC patients[125,126]. However, phase III clinical data are still missing. In addition, two existing drugs (TLR7 ligand imiquimod, probiotic *Escherichia coli* Nissle) stimulate the production of antimicrobial peptides in IECs, and thus result in reduced colitis activity in mice[127,128]. Finally, Etrolizumab which was mentioned above as an anti-β7 integrin inhibitor, has a second effect with respect to barrier dysfunction. This drug blocks the interaction between αE (CD103) on intestinal T cells with E-cadherin on IECs, and subsequently inhibits the intestinal retention of CD4+ and CD8+ T cells in inflamed sites of IBD. This mechanism is considered to be one of the reasons why etrolizumab was more potent than vedolizumab in reducing accumulation of T cells in the inflamed gut[129]. This result also underscores the need of developing IBD drugs specifically targeting innate immune dysfunction of IECs (summarized in Table 3).

**Current endeavors to identify a novel therapeutic target for IBD using intestinal enteroids/organoids**

Since the group of Hans Clevers and Toshiro Sato successfully generated intestinal enteroids/organoids from intestinal crypts, many studies have been performed using human or mouse intestinal enteroids/organoids not only to investigate general intestinal stem cell physiology but also to identify the pathophysiology of specific intestinal diseases, such as colorectal cancer[130,131], infectious diarrheal diseases[38], metabolic diseases[132,133], and genetic disorders[134]. Studies to date to identify a novel therapeutic target for IBD have only used human ISC not iPSC derived intestinal enteroids/organoids. Although several studies have explored the pathogenesis of IBD using intestinal enteroids/organoids with a goal of identifying novel drug targets, the number of successful studies is small relating to the specific IBD drug development. In this section, we provide a summary of the present status of IBD drug research using intestinal enteroids/organoids.

***Comparative study among intestinal enteroids/organoids derived from control and IBD patients for discovery of novel target molecule***

A previous study found a novel drug target IL-1 decoy receptor (IL-1R2) which is highly expressed in IECs in UC patients in remission compared with those in patients with active UC and in healthy controls. This decoy receptor blocks the IL-1β dependent inflammatory mechanism. The addition of an anti-IL-1R2-blocking antibody significantly enhanced IL-1β-dependent transcription of pro-inflammatory chemokines such as CXCL1, CXCL2, and CCL20 in intestinal enteroids/organoids from UC patients in remission. However, there was no significant difference in intestinal enteroids/organoids from healthy controls. Thus, IL-1 R2 may be a novel drug target to promote remission in UC[135].

Rare subtypes of IBD with very early-onset in early childhood (VEO-IBD) are more likely to be associated with specific genetic mutations, especially associated with immune dysfunction, including in IL-10, IL-10R, XIAP, NCF2, or TTC7. These do not occur in IBD in older children[136]. Using enteroids derived from these young patients can lead to the discovery of compounds which are able to normalize the consequence of those mutations. For example, intestinal enteroids grown from children with multiple intestinal atresia, a rare congenital disease with IBD-like features by TTC7A mutations, displayed an inversion of apical-basal polarity of the epithelial cells that was reversed by Rho kinase inhibitor[137]. More recently, whereas TRAIL stimulation induced caspase-3 cleavage and cell death in intestinal enteroids derived from healthy donors, caspase-8 deficient intestinal enteroids derived from a VEO-IBD patient were unresponsive to TRAIL, revealing caspase-8 deficiency as a novel cause for VEO-IBD associated with defective epithelial cell death response[138].

Recently, several studies have compared the profiles of gene expression and DNA methylation in intestinal enteroids/organoids derived from control and IBD patients[14,27,28]. A group of genes were differentially regulated in the intestinal enteroids/organoids of UC patients, including genes associated with antimicrobial defense (LYZ, PLA2G2A) and with mucus secretory functions (ZG16, CLCA1) compared with intestinal enteroids/organoids of non-IBD subjects[14]. These genes which are associated with epithelial barrier dysfunction might be potential drug targets for future IBD therapy.

***Development of intestinal enteroid/organoid-based IBD model by administration of conditions mimicking IBD***

In the IBD environment, several luminal and lamina propria factors such as microbes, cytokines, drugs, and metabolites contribute to the epithelial dysfunction, and subsequently result in the initiation and progression of IBD. Therefore, adding these conditions to intestinal enteroid/organoid culture models might more closely recapitulate the IBD pathophysiology. Previous studies have added diverse IBD related factors (cytokines, bacterial components, metabolites, and niche factors for ISCs) to organoid cultures to model the epithelial barrier dysfunctions in IBD[19,109,139-141].

In terms of physical barrier dysfunction, the target molecules which contribute to epithelial apoptosis or regeneration after injury have been studied. For example, IFN-γ strongly and rapidly induces degranulation and extrusion of Paneth cells in intestinal enteroids/organoids. Furthermore, prolonged stimulation with recombinant IFN-γ (1 ng/ml) reduced intestinal enteroid/organoid growth and caused progressive loss of Paneth cells due to apoptosis[139]. Therefore, this study not only showed that the intestinal enteroid/organoid culture is a useful model to investigate Paneth cell dysfunction in IBD, but also suggested that the pharmacologic modulation of IFN-γ signaling may allow a new strategy to correct Paneth cell dysfunction and survival in IBD.

TNF-α is another pro-inflammatory mediator that plays an integral role in IBD pathogenesis. This cytokine was used to disrupt intestinal enteroids/organoids to recapitulate epithelial apoptosis in IBD[19]. Meanwhile, other studies have found several niche factors for ISCs which may act to promote epithelial proliferation and regeneration after injury. The epithelial regeneration is critical to maintain the physical barrier function after intestinal injury. Previous studies have already reported that several niche factors for ISCs such as Wnt, Notch, and EGF support Lgr5+ ISCs for normal epithelial maintenance[21,142]. A recent study found that IL-22, which is produced from ILCs after tissue injury, also augmented the growth of intestinal enteroids/organoids and proliferation of ISCs *via* the IL-22/STAT3 phosphorylation pathway. Treatment with IL-22 promoted the recovery of ISCs and epithelial regeneration in injured enteroids after irradiation. Thus, IL-22/STAT3 signaling might be a potential drug target to promote mucosal healing in IBD[109]. Similarly, a co-receptor for IL-6 (gp130) promoted the regeneration of intestinal enteroids/organoids by activating YAP and Notch signaling, which underscores that normalization of IL-6 signaling, rather than complete inhibition, may be a future therapeutic approach to improve epithelial regeneration in IBD[143]. In addition, bacterial metabolites, including short-chain fatty acids (SCFAs), increased the size and the number of buds per enteroids/organoids, which supports that commensal bacteria reinforce epithelial barrier function by inducing proliferation of IECs with SCFAs production[11,140]. Following disruption of the epithelial barrier, a transient, specialized repair cell type, wound-associated epithelial (WAE) cells rapidly migrate and seal the epithelial defects (termed restitution)[144]. A previous study using intestinal enteroids/organoids demonstrated that PGE2/EP4 signaling also promotes epithelial regeneration after injury by driving ISCs to differentiate toward WAE cells [145].

Furthermore, there are several studies that model the biochemical- and innate immune-epithelial barrier functions which are relevant to IBD. Colonic enteroids/organoids (termed colonoids) derived monolayers were differentiated to study the interaction of *Enterohemorrhagic Escherichia coli* (EHEC) and human colonic epithelium, which mimic some aspects of host-pathogen interaction in IBD. Colonized EHEC reduced mucus production of colonoids and destroyed the mucus layer[146]. EHEC strain O157:H7 is known to block the IFN-γ/STAT1 pathway in epithelial cells[147]. This mechanism is very similar to the pathogenic feature of adherent invasive *Escherichia coli* (AIECs) isolated from CD patients, which has been implicated in the pathogenesis of CD and is known to suppress the IFN-γ/STAT1 pathway in IECs. This suggests this bacteria might induce an inappropriate anti-microbial response in CD[148,149]. Therefore, these human enteroid monolayer cultures might also be used as a relevant pathophysiologic model that allow the study of the role of AIECs in the context of biochemical barrier dysfunction in IBD. CD is thought to result from an inappropriate inflammatory response directed toward commensal enteric microflora and specific bacterial antigens targeted by this immune response have been studied. Especially, bacterial flagellin (TLR5 ligand) appears to be one such target of the CD-associated immune response[150-152]. Flagellin-specific serum IgG was elevated in patients with CD, but not in patients with UC or in controls, which suggests that flagellin is an antigenic target of the elevated adaptive immune response in CD[150-152]. Flagellin is known to be associated with pro-inflammatory IEC activation as well as pro-fibrotic myofibroblast activation[153-155]. In a recent study, human colonoids from healthy individuals were exposed basolaterally to diverse TLR ligands including (TLR2, TLR4, and TLR5) to investigate the pro-inflammatory response. Flagellin stimulated an increase in both IL-8 and TNF-α transcripts in colonoids in contrast to TLR2 and TLR4 ligands which failed to induce those cytokines[155]. In this study, pro-inflammatory response to flagellin in colonoids from CD patients was not compared to those from healthy individuals. It remains to be determined what the roles of the flagellin and TLR5 receptor are in colonic epithelial cells in CD.

PGE2 is a well-known mediator that promotes diarrhea in IBD by directly activating chloride (Cl-) and fluid secretion through the CFTR on the apical surface of IECs[156-158]. The expression of PGE2 is upregulated in the inflammatory mucosa of IBD patients, where other inflammatory cytokines are also abundant. In a recent study using intestinal enteroids/organoids established from uninflamed mucosa of CD patients, short-term treatment with cytokines such as TNF-α, IL-1β, IL-6, or IFN-γ alone failed to induce a secretory response of enteroids, while PGE2 alone induced enteroid swelling. Furthermore, none of the tested cytokines was able to affect the PGE2-induced enteroid swelling, which suggests the possibility that PGE2 may act as a robust and direct mediator of fluid secretion from IECs and the PGE2 level might determine the local secretory response of IECs without the involvement of other inflammatory cytokines[159]. However, further comparative studies using enteroids from the inflamed mucosa of IBD patients are required to elucidate what the specific role of PGE2 is in the pathophysiology of inflammatory IBD diarrhea.

More recently, to describe long-term epithelial responses to inflammatory stimulation mimicking chronic IBD, a mixture of cytokines and bacterial components were added to the intestinal enteroid/organoid model for 60 weeks. In this study, long-term inflammation led to sustained NF-kB activation and reactive oxygen species (ROS) production even 11 weeks after the removal of the inflammatory mixture. A perpetual NF-kB activation in IECs has been implicated in innate immune dysfunction of IECs in IBD[71,72]. Therefore, this long-term intestinal enteroid/organoid model with sustained NF-kB activation has the potential to recapitulate the perpetual inflammatory activity in mucosa of IBD. Additionally, this result suggests that the long-term inflammatory stimulation might transform intestinal enteroids/organoids into a stressed cellular state, which might be related to the etiology of colitis-associated cancer in UC[48]. In the context of long-term complication of IBD, our previous study used synergistic treatment of TNF-α and TGFβ to generate an intestinal enteroid/organoid model recapitulating epithelial mesenchymal transition (EMT), which might provide a cellular source of myofibroblasts and contribute to intestinal fibrosis in CD[160].

***Development of intestinal enteroids/organoids-based IBD model by co-culturing with other cell components***

In IBD pathogenesis, IECs interact with diverse types of cells including immune cells, mesenchymal cells and neuronal cells. Thus, co-culturing intestinal enteroids/organoids and other cell components can provide a more complex model which includes cell-to-cell interactions, to more closely elucidate the in vivo pathophysiology of IBD. So far, the number of studies co-culturing enteroids/organoids with other cells to specifically investigate IBD pathogenesis is limited. Most co-culture studies have examined the role of other cells for the growth of intestinal enteroids/organoids which is associated with physical barrier function of IECs. For example, to evaluate the role of ILC3s for IECs, lamina propria ILC3s capable of producing IL-22 were co-cultured with intestinal enteroids/organoids. ILC3s markedly increased the size of intestinal enteroids/organoids, and this phenomenon was blocked by an anti-IL-22 neutralizing antibody. Therefore, this co-culture model revealed that immune cells are able to activate ISCs to promote proliferation[109]. Moreover, as a potent supporter of intestinal barrier, the diverse roles of IL-22 producing ILC3s have been reported including promoting epithelial proliferation and inducing anti-microbial peptide and mucin production. In the majority of human studies, the differential frequencies of ILC3 subsets are critically involved in the pathogenesis of CD. Protective NKp44+, IL-22 producing ILC3 subset was found to be decreased whereas the frequency of the IL-17- and IFN-γ-producing CD56- subset of ILC3 was increased in the intestine of CD patients[110,161]. Therefore, this co-culture model of intestinal enteroids/organoids and ILC3 might provide a valuable tool to study IECs-ILC3 interaction in IBD. Another epithelial cell type, tuft cell, has been shown to express the doublecortin-like kinase 1 protein (DCLK1) as a specific marker. DCLK1+ tuft cell cannot survive under standard organoid culture condition. A recent study established a co-culture model of primary neurons and intestinal enteroids/organoids and found that nerves can prolong the survival of DLCK+ tuft cells in vitro. Surprisingly, they also demonstrated that DLCK+ tuft cells give rise to poorly differentiated colorectal cancer after inflammatory injury, suggesting that DLCK+ tuft cells might serve to initiate CAC in IBD[162]. Thus, this system should be further developed as a CAC model in IBD.

Noel *et al*[163]generated a human macrophage-intestinal enteroid/organoid co-culture system and showed that macrophages (M0) enhance physical barrier function and maturity of intestinal organoid monolayers as demonstrated by trans-epithelial electrical resistance and cell height. Although the two effector macrophages (M1 and M2) which are involved in IBD pathogenesis, were not included in this study, this system can be further developed to investigate the interaction between IECs and macrophages in the context of innate immune function of IECs[163]. Emerging evidences have suggested that mesenteric adipose tissue may play a critical role in the inflammatory and fibrotic pathogenesis in CD. In CD, longitudinal ulcerations are located primarily along the mesenteric attachment and the “creeping fat” is known to be implicated in muscular hypertrophy and subsequent stricture formation in CD[164,165]. Recently, the co-culture of intestinal enteroids/organoids and adipocytes revealed a reciprocal inflammatory activation between these cell types, which suggests that adipocytes can be a promising drug target for CD treatment[166].

**The obstacles to overcome in using intestinal enteroids/organoids as an IBD research tool**

Although intestinal enteroid/organoid culture system has many advantages over the conventional IEC models, there are multiple issues to resolve before researchers use intestinal enteroids/organoids as a platform to develop novel IBD drugs.

***The drawbacks of intestinal enteroid/organoid culture conditions***

Cost is a big drawback of intestinal enteroid/organoid cultures. Currently, a significant amount of expensive Matrigel, which is derived from mouse sarcoma cells, is required to propagate intestinal enteroids/organoids. The culture medium contains a myriad of growth factors which have multiple sources such as conditioned media from cell lines and purified recombinant proteins. Both Matrigel and growth factors from conditioned media contain varying amounts of xenogeneic and undefined components, along with the potential risk of pathogen/immunogen transmission and batch-to-batch variability[38,167,168].

Considering the recent progress in establishing human enteroids as a model of infectious diarrheal diseases, human enteroid/organoid culture conditions might provide a relevant pathophysiologic model to study microbiota-epithelium interactions[38,146]. However, to develop a more reliable model, ways to co-culture the primarily anaerobic gut microbiota, which consists of many bacterial species, with human enteroids in anerobic culture conditions without damaging the enteroids is a significant challenge to be overcome[9]. Moreover, intestinal enteroid/organoid culture systems lack physiological luminal and blood flow and the repetitive contractions of peristalsis, which are known to result in altered gene expression and cell function/morphology[168]. In this regard, an emerging microfluidic chamber system combining peristalsis-like stretch with apical and basolateral liquid flow (gut-on-a-chip) might be a way to overcome these drawbacks of enteroid/organoid cultures. Most recently, a novel microfluidic device with a transluminal hypoxia gradient was developed for co-culturing a complex living human gut microbiome, including obligate anaerobes with human intestinal epithelium, that until now has only included Caco-2 cells[169].

***The issues related to intestinal enteroids/organoids derived from patients with IBD***

In the mucosa of active IBD, excessive cell death is observed in the ileal and colonic epithelium due to a highly inflammatory and pro-apoptotic milieu within the lamina propria[170]. Therefore, the number and quality of isolated intestinal crypts and ISCs might be too low to regularly form intestinal enteroids/organoids as well as to maintain long-term culture. In particular, the intestinal crypts isolated from actively inflamed lesion in CD, in our experience, showed low yields of intestinal enteroid/organoid formation. Moreover, a recent study mentioned the difficulty of generating intestinal enteroids/organoids, even from the normal mucosa of UC patients due to crypt distortion[47]. These observations suggest that the current protocols to isolate and culture intestinal enteroids/organoids might not be sufficient for generating enteroid/organoid banks of actively inflamed IBD. A few studies reported that the intestinal enteroid/organoid-forming capacity is not lower in the crypts or ISCs derived from patients with active CD than in those derived from patients with inactive IBD or from healthy controls[14,27,171]. However, the severity of inflamed mucosa which was used to isolate intestinal enteroids/organoids was not standardized among those studies, which might affect the intestinal enteroid/organoid-forming capacity. The number of published studies which have used intestinal enteroids/organoids derived from actively inflamed lesions of IBD, especially CD, is still very limited.

As a surrogate of IECs in IBD, whether the intestinal enteroids/organoids derived from IBD patients will resemble the inflammatory phenotype of the tissues of origin on the long-term culture is another issue to be elucidated. Although several studies have suggested that the intestinal enteroids/organoids from patients with IBD retain the disease-specific DNA methylation and gene expression changes which might be imprinted in ISCs, a recent study showed that the expression of IFN-γ and IL-1β appeared to be significantly lower in intestinal enteroids/organoids derived from patients with IBD compared with biopsies used to form these intestinal enteroids/organoids. This suggests that inflammatory phenotype at the mRNA level in biopsies may not be propagated to intestinal enteroids/organoids, and a pro-inflammatory stimulation might be required for sustained expression of the inflammatory phenotype. However, in this study, whole tissue with inflammatory cells was compared to enteroids without inflammatory cells. Thus, status of inflammation in IBD enteroids over passages needs determination. Furthermore, considering that there was a trend that the expression of IFN-γ in UC inflamed organoids was higher than in control organoids and that limited numbers of IBD patients (n = 3-7 for each group) were enrolled to isolate enteroids/organoids in this study, further studies are needed to elucidate whether the transcription profiles of enterods/organoids will remain identical or similar to those of the inflamed tissues of origin in IBD[48,171].

**Conclusion**

Although IBD is a multifactorial and heterogeneous disease, the therapeutic approaches over the last decades have been intensively focusing on immune cells and anti-inflammatory mechanisms. Moreover, despite the therapeutic advances including novel biologics, a significant number of IBD patients still do not achieve long-term remission and mucosal healing, which are very important for the quality of life and the prognosis of these patients.

The emerging evidence has underscored that the intestinal epithelium has a crucial role in maintaining mucosal homeostasis and regulating immune cells as a physical, biochemical and innate immune barrier. Moreover, epithelial barrier dysfunction is regarded as a critical mechanism in development and perpetuation of IBD. However, as described through this review, the current therapeutic approaches in IBD focused on epithelial barrier dysfunction are still limited. Compared with conventional IEC cultures, a novel intestinal enteroid/organoid culture might provide advantages to recapitulate the in vivo physiology of human intestinal epithelium, which makes it a promising tool for modeling the pathophysiology of IBD. However, the number of published studies using the intestinal enteroid/organoid model to specifically identify drug targets for IBD treatment is thus far small. More diverse therapeutic approaches may ultimately overcome the limitations of current therapeutic options. Therefore, IBD drug research focusing on epithelial dysfunction with a novel intestinal enteroid/organoid system should be evaluated as a future way to develop additional therapeutic approaches of IBD.

**REFERENCES**

1 **Okamoto R**, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. *J Gastroenterol* 2016; **51**: 11-21 [PMID: 26138071 DOI: 10.1007/s00535-015-1098-4]

2 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

3 **Frolkis AD**, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. *Gastroenterology* 2013; **145**: 996-1006 [PMID: 23896172 DOI: 10.1053/j.gastro.2013.07.041]

4 **Ruffolo C**, Scarpa M, Bassi N. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010; **363**: 1086-1087; author reply 1087-1088 [PMID: 20848681 DOI: 10.1056/NEJMc1005805]

5 **Feagan BG**, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *N Engl J Med* 2016; **375**: 1946-1960 [PMID: 27959607 DOI: 10.1056/NEJMoa1602773]

6 **Sandborn WJ**, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2013; **369**: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215739]

7 **Sands BE**, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. *Inflamm Bowel Dis* 2017; **23**: 97-106 [PMID: 27930408 DOI: 10.1097/mib.0000000000000979]

8 **Feagan BG**, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013; **369**: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]

9 **Dotti I**, Salas A. Potential Use of Human Stem Cell-Derived Intestinal Organoids to Study Inflammatory Bowel Diseases. *Inflamm Bowel Dis* 2018; **24**: 2501-2509 [PMID: 30169820 DOI: 10.1093/ibd/izy275]

10 **McCole DF**. IBD candidate genes and intestinal barrier regulation. *Inflamm Bowel Dis* 2014; **20**: 1829-1849 [PMID: 25215613 DOI: 10.1097/mib.0000000000000090]

11 **Peterson LW**, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol* 2014; **14**: 141-153 [PMID: 24566914 DOI: 10.1038/nri3608]

12 **Pastorelli L**, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. *Front Immunol* 2013; **4**: 280 [PMID: 24062746 DOI: 10.3389/fimmu.2013.00280]

13 **Mao R**, Hu PJ. The Future of IBD Therapy: Where Are We and Where Should We Go Next? *Dig Dis* 2016; **34**: 175-179 [PMID: 26982457 DOI: 10.1159/000443135]

14 **Dotti I**, Mora-Buch R, Ferrer-Picón E, Planell N, Jung P, Masamunt MC, Leal RF, Martín de Carpi J, Llach J, Ordás I, Batlle E, Panés J, Salas A. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. *Gut* 2017; **66**: 2069-2079 [PMID: 27803115 DOI: 10.1136/gutjnl-2016-312609]

15 **Planell N**, Lozano JJ, Mora-Buch R, Masamunt MC, Jimeno M, Ordás I, Esteller M, Ricart E, Piqué JM, Panés J, Salas A. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. *Gut* 2013; **62**: 967-976 [PMID: 23135761 DOI: 10.1136/gutjnl-2012-303333]

16 **Cooke J**, Zhang H, Greger L, Silva AL, Massey D, Dawson C, Metz A, Ibrahim A, Parkes M. Mucosal genome-wide methylation changes in inflammatory bowel disease. *Inflamm Bowel Dis* 2012; **18**: 2128-2137 [PMID: 22419656 DOI: 10.1002/ibd.22942]

17 **Mirza AH**, Berthelsen CH, Seemann SE, Pan X, Frederiksen KS, Vilien M, Gorodkin J, Pociot F. Transcriptomic landscape of lncRNAs in inflammatory bowel disease. *Genome Med* 2015; **7**: 39 [PMID: 25991924 DOI: 10.1186/s13073-015-0162-2]

18 **Booth C**, O'Shea JA, Potten CS. Maintenance of functional stem cells in isolated and cultured adult intestinal epithelium. *Exp Cell Res* 1999; **249**: 359-366 [PMID: 10366435 DOI: 10.1006/excr.1999.4483]

19 **Grabinger T**, Luks L, Kostadinova F, Zimberlin C, Medema JP, Leist M, Brunner T. Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy. *Cell Death Dis* 2014; **5**: e1228 [PMID: 24832600 DOI: 10.1038/cddis.2014.183]

20 **Grossmann J**, Maxson JM, Whitacre CM, Orosz DE, Berger NA, Fiocchi C, Levine AD. New isolation technique to study apoptosis in human intestinal epithelial cells. *Am J Pathol* 1998; **153**: 53-62 [PMID: 9665465 DOI: 10.1016/s0002-9440(10)65545-9]

21 **Sato T**, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature* 2009; **459**: 262-265 [PMID: 19329995 DOI: 10.1038/nature07935]

22 **Sato T**, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 2011; **141**: 1762-1772 [PMID: 21889923 DOI: 10.1053/j.gastro.2011.07.050]

23 **Jung P**, Sato T, Merlos-Suárez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E. Isolation and in vitro expansion of human colonic stem cells. *Nat Med* 2011; **17**: 1225-1227 [PMID: 21892181 DOI: 10.1038/nm.2470]

24 **Takahashi T**. Organoids for Drug Discovery and Personalized Medicine. *Annu Rev Pharmacol Toxicol* 2019; **59**: 447-462 [PMID: 30113875 DOI: 10.1146/annurev-pharmtox-010818-021108]

25 **Middendorp S**, Schneeberger K, Wiegerinck CL, Mokry M, Akkerman RD, van Wijngaarden S, Clevers H, Nieuwenhuis EE. Adult stem cells in the small intestine are intrinsically programmed with their location-specific function. *Stem Cells* 2014; **32**: 1083-1091 [PMID: 24496776 DOI: 10.1002/stem.1655]

26 **Kraiczy J**, Nayak KM, Howell KJ, Ross A, Forbester J, Salvestrini C, Mustata R, Perkins S, Andersson-Rolf A, Leenen E, Liebert A, Vallier L, Rosenstiel PC, Stegle O, Dougan G, Heuschkel R, Koo BK, Zilbauer M. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. *Gut* 2019; **68**: 49-61 [PMID: 29141958 DOI: 10.1136/gutjnl-2017-314817]

27 **Suzuki K**, Murano T, Shimizu H, Ito G, Nakata T, Fujii S, Ishibashi F, Kawamoto A, Anzai S, Kuno R, Kuwabara K, Takahashi J, Hama M, Nagata S, Hiraguri Y, Takenaka K, Yui S, Tsuchiya K, Nakamura T, Ohtsuka K, Watanabe M, Okamoto R. Single cell analysis of Crohn's disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties. *J Gastroenterol* 2018; **53**: 1035-1047 [PMID: 29374777 DOI: 10.1007/s00535-018-1437-3]

28 **Howell KJ**, Kraiczy J, Nayak KM, Gasparetto M, Ross A, Lee C, Mak TN, Koo BK, Kumar N, Lawley T, Sinha A, Rosenstiel P, Heuschkel R, Stegle O, Zilbauer M. DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate Disease Subtypes and Associate With Outcome. *Gastroenterology* 2018; **154**: 585-598 [PMID: 29031501 DOI: 10.1053/j.gastro.2017.10.007]

29 **Dedhia PH**, Bertaux-Skeirik N, Zavros Y, Spence JR. Organoid Models of Human Gastrointestinal Development and Disease. *Gastroenterology* 2016; **150**: 1098-1112 [PMID: 26774180 DOI: 10.1053/j.gastro.2015.12.042]

30 **Spence JR**, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature* 2011; **470**: 105-109 [PMID: 21151107 DOI: 10.1038/nature09691]

31 **Rodansky ES**, Johnson LA, Huang S, Spence JR, Higgins PD. Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs. *Exp Mol Pathol* 2015; **98**: 346-351 [PMID: 25828392 DOI: 10.1016/j.yexmp.2015.03.033]

32 **Zachos NC**, Kovbasnjuk O, Foulke-Abel J, In J, Blutt SE, de Jonge HR, Estes MK, Donowitz M. Human Enteroids/Colonoids and Intestinal Organoids Functionally Recapitulate Normal Intestinal Physiology and Pathophysiology. *J Biol Chem* 2016; **291**: 3759-3766 [PMID: 26677228 DOI: 10.1074/jbc.R114.635995]

33 **Lesuffleur T**, Porchet N, Aubert JP, Swallow D, Gum JR, Kim YS, Real FX, Zweibaum A. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. *J Cell Sci* 1993; **106 (Pt 3)**: 771-783 [PMID: 8308060]

34 **Sambuy Y**, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. *Cell Biol Toxicol* 2005; **21**: 1-26 [PMID: 15868485 DOI: 10.1007/s10565-005-0085-6]

35 **Howitt MR**, Lavoie S, Michaud M, Blum AM, Tran SV, Weinstock JV, Gallini CA, Redding K, Margolskee RF, Osborne LC, Artis D, Garrett WS. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. *Science* 2016; **351**: 1329-1333 [PMID: 26847546 DOI: 10.1126/science.aaf1648]

36 **Bellono NW**, Bayrer JR, Leitch DB, Castro J, Zhang C, O'Donnell TA, Brierley SM, Ingraham HA, Julius D. Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways. *Cell* 2017; **170**: 185-198.e16 [PMID: 28648659 DOI: 10.1016/j.cell.2017.05.034]

37 **de Lau W**, Kujala P, Schneeberger K, Middendorp S, Li VS, Barker N, Martens A, Hofhuis F, DeKoter RP, Peters PJ, Nieuwenhuis E, Clevers H. Peyer's patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured "miniguts". *Mol Cell Biol* 2012; **32**: 3639-3647 [PMID: 22778137 DOI: 10.1128/mcb.00434-12]

38 **Foulke-Abel J**, In J, Kovbasnjuk O, Zachos NC, Ettayebi K, Blutt SE, Hyser JM, Zeng XL, Crawford SE, Broughman JR, Estes MK, Donowitz M. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. *Exp Biol Med (Maywood)* 2014; **239**: 1124-1134 [PMID: 24719375 DOI: 10.1177/1535370214529398]

39 **Ganguli K**, Collado MC, Rautava J, Lu L, Satokari R, von Ossowski I, Reunanen J, de Vos WM, Palva A, Isolauri E, Salminen S, Walker WA, Rautava S. Lactobacillus rhamnosus GG and its SpaC pilus adhesin modulate inflammatory responsiveness and TLR-related gene expression in the fetal human gut. *Pediatr Res* 2015; **77**: 528-535 [PMID: 25580735 DOI: 10.1038/pr.2015.5]

40 **Nanthakumar NN**, Fusunyan RD, Sanderson I, Walker WA. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. *Proc Natl Acad Sci USA* 2000; **97**: 6043-6048 [PMID: 10823949 DOI: 10.1073/pnas.97.11.6043]

41 **MacDonald TT**, Spencer J. Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. *J Exp Med* 1988; **167**: 1341-1349 [PMID: 2965735 DOI: 10.1084/jem.167.4.1341]

42 **Al-Lamki RS**, Bradley JR, Pober JS. Human Organ Culture: Updating the Approach to Bridge the Gap from *In Vitro* to *In Vivo* in Inflammation, Cancer, and Stem Cell Biology. *Front Med (Lausanne)* 2017; **4**: 148 [PMID: 28955710 DOI: 10.3389/fmed.2017.00148]

43 **Kang TH**, Kim HJ. Farewell to Animal Testing: Innovations on Human Intestinal Microphysiological Systems. *Micromachines (Basel)* 2016; **7**: [PMID: 30404281 DOI: 10.3390/mi7070107]

44 **Kozuka K**, He Y, Koo-McCoy S, Kumaraswamy P, Nie B, Shaw K, Chan P, Leadbetter M, He L, Lewis JG, Zhong Z, Charmot D, Balaa M, King AJ, Caldwell JS, Siegel M. Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform. *Stem Cell Reports* 2017; **9**: 1976-1990 [PMID: 29153987 DOI: 10.1016/j.stemcr.2017.10.013]

45 **Cil O**, Phuan PW, Gillespie AM, Lee S, Tradtrantip L, Yin J, Tse M, Zachos NC, Lin R, Donowitz M, Verkman AS. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. *FASEB J* 2017; **31**: 751-760 [PMID: 27871064 DOI: 10.1096/fj.201600891R]

46 **Schwank G**, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EE, Beekman JM, Clevers H. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* 2013; **13**: 653-658 [PMID: 24315439 DOI: 10.1016/j.stem.2013.11.002]

47 **Nishimura R**, Shirasaki T, Tsuchiya K, Miyake Y, Watanabe Y, Hibiya S, Watanabe S, Nakamura T, Watanabe M. Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids. *J Gastroenterol* 2019; **54**: 608-620 [PMID: 30599053 DOI: 10.1007/s00535-018-01540-y]

48 **Hibiya S**, Tsuchiya K, Hayashi R, Fukushima K, Horita N, Watanabe S, Shirasaki T, Nishimura R, Kimura N, Nishimura T, Gotoh N, Oshima S, Okamoto R, Nakamura T, Watanabe M. Long-term Inflammation Transforms Intestinal Epithelial Cells of Colonic Organoids. *J Crohns Colitis* 2017; **11**: 621-630 [PMID: 28453760 DOI: 10.1093/ecco-jcc/jjw186]

49 **Liang G**, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. *Cell Stem Cell* 2013; **13**: 149-159 [PMID: 23910082 DOI: 10.1016/j.stem.2013.07.001]

50 **Behjati S**, Huch M, van Boxtel R, Karthaus W, Wedge DC, Tamuri AU, Martincorena I, Petljak M, Alexandrov LB, Gundem G, Tarpey PS, Roerink S, Blokker J, Maddison M, Mudie L, Robinson B, Nik-Zainal S, Campbell P, Goldman N, van de Wetering M, Cuppen E, Clevers H, Stratton MR. Genome sequencing of normal cells reveals developmental lineages and mutational processes. *Nature* 2014; **513**: 422-425 [PMID: 25043003 DOI: 10.1038/nature13448]

51 **Roda G**, Sartini A, Zambon E, Calafiore A, Marocchi M, Caponi A, Belluzzi A, Roda E. Intestinal epithelial cells in inflammatory bowel diseases. *World J Gastroenterol* 2010; **16**: 4264-4271 [PMID: 20818809 DOI: 10.3748/wjg.v16.i34.4264]

52 **Sturm A**, Dignass AU. Epithelial restitution and wound healing in inflammatory bowel disease. *World J Gastroenterol* 2008; **14**: 348-353 [PMID: 18200658]

53 **Taupin D**, Podolsky DK. Trefoil factors: initiators of mucosal healing. *Nat Rev Mol Cell Biol* 2003; **4**: 721-732 [PMID: 14506475 DOI: 10.1038/nrm1203]

54 **Loncar MB**, Al-azzeh ED, Sommer PS, Marinovic M, Schmehl K, Kruschewski M, Blin N, Stohwasser R, Gött P, Kayademir T. Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide. *Gut* 2003; **52**: 1297-1303 [PMID: 12912861]

55 **Hensel KO**, Boland V, Postberg J, Zilbauer M, Heuschkel R, Vogel S, Gödde D, Wirth S, Jenke AC. Differential expression of mucosal trefoil factors and mucins in pediatric inflammatory bowel diseases. *Sci Rep* 2014; **4**: 7343 [PMID: 25475414 DOI: 10.1038/srep07343]

56 **Kondo S**, Araki T, Toiyama Y, Tanaka K, Kawamura M, Okugawa Y, Okita Y, Saigusa S, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer. *Oncol Lett* 2018; **16**: 3658-3664 [PMID: 30127975 DOI: 10.3892/ol.2018.9120]

57 **Tytgat KM**, van der Wal JW, Einerhand AW, Büller HA, Dekker J. Quantitative analysis of MUC2 synthesis in ulcerative colitis. *Biochem Biophys Res Commun* 1996; **224**: 397-405 [PMID: 8702401 DOI: 10.1006/bbrc.1996.1039]

58 **Yu K**, Lujan R, Marmorstein A, Gabriel S, Hartzell HC. Bestrophin-2 mediates bicarbonate transport by goblet cells in mouse colon. *J Clin Invest* 2010; **120**: 1722-1735 [PMID: 20407206 DOI: 10.1172/jci41129]

59 **Ito G**, Okamoto R, Murano T, Shimizu H, Fujii S, Nakata T, Mizutani T, Yui S, Akiyama-Morio J, Nemoto Y, Okada E, Araki A, Ohtsuka K, Tsuchiya K, Nakamura T, Watanabe M. Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells. *PLoS One* 2013; **8**: e79693 [PMID: 24223998 DOI: 10.1371/journal.pone.0079693]

60 **Bevins CL**, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. *Nat Rev Microbiol* 2011; **9**: 356-368 [PMID: 21423246 DOI: 10.1038/nrmicro2546]

61 **Adolph TE**, Tomczak MF, Niederreiter L, Ko HJ, Böck J, Martinez-Naves E, Glickman JN, Tschurtschenthaler M, Hartwig J, Hosomi S, Flak MB, Cusick JL, Kohno K, Iwawaki T, Billmann-Born S, Raine T, Bharti R, Lucius R, Kweon MN, Marciniak SJ, Choi A, Hagen SJ, Schreiber S, Rosenstiel P, Kaser A, Blumberg RS. Paneth cells as a site of origin for intestinal inflammation. *Nature* 2013; **503**: 272-276 [PMID: 24089213 DOI: 10.1038/nature12599]

62 **Cadwell K**, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW 4th. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature* 2008; **456**: 259-263 [PMID: 18849966 DOI: 10.1038/nature07416]

63 **Wehkamp J**, Wang G, Kübler I, Nuding S, Gregorieff A, Schnabel A, Kays RJ, Fellermann K, Burk O, Schwab M, Clevers H, Bevins CL, Stange EF. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. *J Immunol* 2007; **179**: 3109-3118 [PMID: 17709525]

64 **Rocha JD**, Schlossmacher MG, Philpott DJ. LRRK2 and Nod2 promote lysozyme sorting in Paneth cells. *Nat Immunol* 2015; **16**: 898-900 [PMID: 26287588 DOI: 10.1038/ni.3255]

65 **Wehkamp J**, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange EF, Bevins CL. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. *Proc Natl Acad Sci U S A* 2005; **102**: 18129-18134 [PMID: 16330776 DOI: 10.1073/pnas.0505256102]

66 **Kobayashi KS**, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science* 2005; **307**: 731-734 [PMID: 15692051 DOI: 10.1126/science.1104911]

67 **Otte JM**, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. *Gastroenterology* 2004; **126**: 1054-1070 [PMID: 15057745]

68 **Lotz M**, Gütle D, Walther S, Ménard S, Bogdan C, Hornef MW. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. *J Exp Med* 2006; **203**: 973-984 [PMID: 16606665 DOI: 10.1084/jem.20050625]

69 **Szebeni B**, Veres G, Dezsõfi A, Rusai K, Vannay A, Mraz M, Majorova E, Arató A. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. *Clin Exp Immunol* 2008; **151**: 34-41 [PMID: 17991289 DOI: 10.1111/j.1365-2249.2007.03531.x]

70 **Cario E**, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. *Infect Immun* 2000; **68**: 7010-7017 [PMID: 11083826]

71 **Cho JH**. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 2008; **8**: 458-466 [PMID: 18500230 DOI: 10.1038/nri2340]

72 **Hisamatsu T**, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. *Gastroenterology* 2003; **124**: 993-1000 [PMID: 12671896 DOI: 10.1053/gast.2003.50153]

73 **Dotan I**, Allez M, Nakazawa A, Brimnes J, Schulder-Katz M, Mayer L. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. *Am J Physiol Gastrointest Liver Physiol* 2007; **292**: G1630-G1640 [PMID: 17347451 DOI: 10.1152/ajpgi.00294.2006]

74 **Panja A**, Blumberg RS, Balk SP, Mayer L. CD1d is involved in T cell-intestinal epithelial cell interactions. *J Exp Med* 1993; **178**: 1115-1119 [PMID: 7688787]

75 **Shao L**, Allez M, Park MS, Mayer L. Immunomodulatory roles of the carcinoembryonic antigen family of glycoproteins. *Ann N Y Acad Sci* 2006; **1072**: 194-209 [PMID: 17057200 DOI: 10.1196/annals.1326.037]

76 **Toy LS**, Yio XY, Lin A, Honig S, Mayer L. Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. *J Clin Invest* 1997; **100**: 2062-2071 [PMID: 9329971 DOI: 10.1172/jci119739]

77 **Neurath MF**. Current and emerging therapeutic targets for IBD. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 269-278 [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208]

78 **Allgayer H**. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. *Aliment Pharmacol Ther* 2003; **18 Suppl 2**: 10-14 [PMID: 12950415]

79 **Tiede I**, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. *J Clin Invest* 2003; **111**: 1133-1145 [PMID: 12697733 DOI: 10.1172/jci16432]

80 **Steiner S**, Daniel C, Fischer A, Atreya I, Hirschmann S, Waldner M, Neumann H, Neurath M, Atreya R, Weigmann B. Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis. *Arch Immunol Ther Exp (Warsz)* 2015; **63**: 53-63 [PMID: 25155925 DOI: 10.1007/s00005-014-0309-7]

81 **Matsuda S**, Koyasu S. Mechanisms of action of cyclosporine. *Immunopharmacology* 2000; **47**: 119-125 [PMID: 10878286]

82 **Nielsen CH**, Albertsen L, Bendtzen K, Baslund B. Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. *Clin Exp Immunol* 2007; **148**: 288-295 [PMID: 17286800 DOI: 10.1111/j.1365-2249.2007.03335.x]

83 **Rogler G**. Where are we heading to in pharmacological IBD therapy? *Pharmacol Res* 2015; **100**: 220-227 [PMID: 26277232 DOI: 10.1016/j.phrs.2015.07.005]

84 **Colombel JF**, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010; **362**: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]

85 **Vanhove W**, Nys K, Vermeire S. Therapeutic innovations in inflammatory bowel diseases. *Clin Pharmacol Ther* 2016; **99**: 49-58 [PMID: 26509246 DOI: 10.1002/cpt.286]

86 **Koutruba N**, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. *Ther Clin Risk Manag* 2010; **6**: 123-141 [PMID: 20421912]

87 **Atreya R**, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. *Nat Med* 2000; **6**: 583-588 [PMID: 10802717 DOI: 10.1038/75068]

88 **Danese S**, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). *Gut* 2019; **68**: 40-48 [PMID: 29247068 DOI: 10.1136/gutjnl-2017-314562]

89 **Ito H**, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. *Gastroenterology* 2004; **126**: 989-96; discussion 947 [PMID: 15057738]

90 **Sandborn WJ**, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *N Engl J Med* 2012; **367**: 616-624 [PMID: 22894574 DOI: 10.1056/NEJMoa1112168]

91 **Ghoreschi K**, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *J Immunol* 2011; **186**: 4234-4243 [PMID: 21383241 DOI: 10.4049/jimmunol.1003668]

92 **Withers DR**, Hepworth MR, Wang X, Mackley EC, Halford EE, Dutton EE, Marriott CL, Brucklacher-Waldert V, Veldhoen M, Kelsen J, Baldassano RN, Sonnenberg GF. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. *Nat Med* 2016; **22**: 319-323 [PMID: 26878233 DOI: 10.1038/nm.4046]

93 **Popp V**, Gerlach K, Mott S, Turowska A, Garn H, Atreya R, Lehr HA, Ho IC, Renz H, Weigmann B, Neurath MF. Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice. *Gastroenterology* 2017; **152**: 176-192.e5 [PMID: 27639807 DOI: 10.1053/j.gastro.2016.09.005]

94 **Stallmach A**, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. *Aliment Pharmacol Ther* 2016; **44**: 1199-1212 [PMID: 27714831 DOI: 10.1111/apt.13813]

95 **Vermeire S**, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. *Lancet* 2014; **384**: 309-318 [PMID: 24814090 DOI: 10.1016/s0140-6736(14)60661-9]

96 **Keshav S**, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Rácz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlén P, Schreiber S, Schall TJ, Bekker P; Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. *PLoS One* 2013; **8**: e60094 [PMID: 23527300 DOI: 10.1371/journal.pone.0060094]

97 **Walters MJ**, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. *J Pharmacol Exp Ther* 2010; **335**: 61-69 [PMID: 20660125 DOI: 10.1124/jpet.110.169714]

98 **Hassan-Zahraee M**, Banerjee A, Cheng JB, Zhang W, Ahmad A, Page K, von Schack D, Zhang B, Martin SW, Nayak S, Reddy P, Xi L, Neubert H, Fernandez Ocana M, Gorelick K, Clare R, Vincent M, Cataldi F, Hung K. Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease. *J Crohns Colitis* 2018; **12**: 77-86 [PMID: 28961803 DOI: 10.1093/ecco-jcc/jjx121]

99 **Vermeire S**, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet* 2017; **390**: 135-144 [PMID: 28527704 DOI: 10.1016/s0140-6736(17)30930-3]

100 **Yacyshyn BR**, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR; ISIS 2302-CS9 Investigators. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. *Gut* 2002; **51**: 30-36 [PMID: 12077088]

101 **Sandborn WJ**, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. *N Engl J Med* 2016; **374**: 1754-1762 [PMID: 27144850 DOI: 10.1056/NEJMoa1513248]

102 **Gonzalez-Cabrera PJ**, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. *F1000Prime Rep* 2014; **6**: 109 [PMID: 25580263 DOI: 10.12703/p6-109]

103 **Degagné E**, Saba JD. S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. *Clin Exp Gastroenterol* 2014; **7**: 205-214 [PMID: 25061328 DOI: 10.2147/ceg.s43453]

104 **Monteleone G**, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med* 2015; **372**: 1104-1113 [PMID: 25785968 DOI: 10.1056/NEJMoa1407250]

105 **Ciccocioppo R**, Cangemi GC, Kruzliak P, Gallia A, Betti E, Badulli C, Martinetti M, Cervio M, Pecci A, Bozzi V, Dionigi P, Visai L, Gurrado A, Alvisi C, Picone C, Monti M, Bernardo ME, Gobbi P, Corazza GR. Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact. *Stem Cell Res Ther* 2015; **6**: 137 [PMID: 26206376 DOI: 10.1186/s13287-015-0122-1]

106 **Panés J**, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 2016; **388**: 1281-1290 [PMID: 27477896 DOI: 10.1016/s0140-6736(16)31203-x]

107 **Desreumaux P**, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. *Gastroenterology* 2012; **143**: 1207-1217.e2 [PMID: 22885333 DOI: 10.1053/j.gastro.2012.07.116]

108 **Pickert G**, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, Ouyang W, Neurath MF, Becker C. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. *J Exp Med* 2009; **206**: 1465-1472 [PMID: 19564350 DOI: 10.1084/jem.20082683]

109 **Lindemans CA**, Calafiore M, Mertelsmann AM, O'Connor MH, Dudakov JA, Jenq RR, Velardi E, Young LF, Smith OM, Lawrence G, Ivanov JA, Fu YY, Takashima S, Hua G, Martin ML, O'Rourke KP, Lo YH, Mokry M, Romera-Hernandez M, Cupedo T, Dow L, Nieuwenhuis EE, Shroyer NF, Liu C, Kolesnick R, van den Brink MRM, Hanash AM. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. *Nature* 2015; **528**: 560-564 [PMID: 26649819 DOI: 10.1038/nature16460]

110 **Li LJ**, Gong C, Zhao MH, Feng BS. Role of interleukin-22 in inflammatory bowel disease. *World J Gastroenterol* 2014; **20**: 18177-18188 [PMID: 25561785 DOI: 10.3748/wjg.v20.i48.18177]

111 **Pelczar P**, Witkowski M, Perez LG, Kempski J, Hammel AG, Brockmann L, Kleinschmidt D, Wende S, Haueis C, Bedke T, Witkowski M, Krasemann S, Steurer S, Booth CJ, Busch P, König A, Rauch U, Benten D, Izbicki JR, Rösch T, Lohse AW, Strowig T, Gagliani N, Flavell RA, Huber S. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. *Science* 2016; **354**: 358-362 [PMID: 27846573 DOI: 10.1126/science.aah5903]

112 **Cao SS**, Zimmermann EM, Chuang BM, Song B, Nwokoye A, Wilkinson JE, Eaton KA, Kaufman RJ. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. *Gastroenterology* 2013; **144**: 989-1000.e6 [PMID: 23336977 DOI: 10.1053/j.gastro.2013.01.023]

113 **Suzuki A**, Sekiya S, Gunshima E, Fujii S, Taniguchi H. EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long-term monolayer cell culture. *Lab Invest* 2010; **90**: 1425-1436 [PMID: 20714325 DOI: 10.1038/labinvest.2010.150]

114 **Sinha A**, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. *N Engl J Med* 2003; **349**: 350-357 [PMID: 12878742 DOI: 10.1056/NEJMoa013136]

115 **Paterson BM**, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. *Aliment Pharmacol Ther* 2007; **26**: 757-766 [PMID: 17697209 DOI: 10.1111/j.1365-2036.2007.03413.x]

116 **Shah A**, Walker M, Burger D, Martin N, von Wulffen M, Koloski N, Jones M, Talley NJ, Holtmann GJ. Link Between Celiac Disease and Inflammatory Bowel Disease. *J Clin Gastroenterol* 2018; [Epub ahead of print] [PMID: 29762265 DOI: 10.1097/mcg.0000000000001033]

117 **Kong J**, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol* 2008; **294**: G208-G216 [PMID: 17962355 DOI: 10.1152/ajpgi.00398.2007]

118 **Braniste V**, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. *J Physiol* 2009; **587**: 3317-3328 [PMID: 19433574 DOI: 10.1113/jphysiol.2009.169300]

119 **Chen L**, Wang J, You Q, He S, Meng Q, Gao J, Wu X, Shen Y, Sun Y, Wu X, Xu Q. Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin. *Front Pharmacol* 2018; **9**: 761 [PMID: 30061832 DOI: 10.3389/fphar.2018.00761]

120 **Nakase H**, Fujiyama Y, Oshitani N, Oga T, Nonomura K, Matsuoka T, Esaki Y, Murayama T, Teramukai S, Chiba T, Narumiya S. Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. *Inflamm Bowel Dis* 2010; **16**: 731-733 [PMID: 19760781 DOI: 10.1002/ibd.21080]

121 **Hatayama H**, Iwashita J, Kuwajima A, Abe T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. *Biochem Biophys Res Commun* 2007; **356**: 599-603 [PMID: 17374366 DOI: 10.1016/j.bbrc.2007.03.025]

122 **Tai EK**, Wong HP, Lam EK, Wu WK, Yu L, Koo MW, Cho CH. Cathelicidin stimulates colonic mucus synthesis by up-regulating MUC1 and MUC2 expression through a mitogen-activated protein kinase pathway. *J Cell Biochem* 2008; **104**: 251-258 [PMID: 18059019 DOI: 10.1002/jcb.21615]

123 **Belley A**, Chadee K. Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor. *Gastroenterology* 1999; **117**: 1352-1362 [PMID: 10579976]

124 **Chen G**, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. *EBioMedicine* 2018; **30**: 317-325 [PMID: 29627390 DOI: 10.1016/j.ebiom.2018.03.030]

125 **Stremmel W**, Hanemann A, Ehehalt R, Karner M, Braun A. Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis? *Dig Dis* 2010; **28**: 490-496 [PMID: 20926877 DOI: 10.1159/000320407]

126 **Karner M**, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W. First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. *Am J Gastroenterol* 2014; **109**: 1041-1051 [PMID: 24796768 DOI: 10.1038/ajg.2014.104]

127 **Sainathan SK**, Bishnupuri KS, Aden K, Luo Q, Houchen CW, Anant S, Dieckgraefe BK. Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. *Inflamm Bowel Dis* 2012; **18**: 955-967 [PMID: 21953855 DOI: 10.1002/ibd.21867]

128 **Scaldaferri F**, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. *World J Gastroenterol* 2016; **22**: 5505-5511 [PMID: 27350728 DOI: 10.3748/wjg.v22.i24.5505]

129 **Zundler S**, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, Neufert C, Atreya I, Neurath MF. Blockade of αEβ7 integrin suppresses accumulation of CD8<sup>+</sup> and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. *Gut* 2017; **66**: 1936-1948 [PMID: 27543429 DOI: 10.1136/gutjnl-2016-312439]

130 **Drost J**, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H, Korving J, van de Wetering M, Schwank G, Logtenberg M, Cuppen E, Snippert HJ, Medema JP, Kops GJ, Clevers H. Sequential cancer mutations in cultured human intestinal stem cells. *Nature* 2015; **521**: 43-47 [PMID: 25924068 DOI: 10.1038/nature14415]

131 **Matano M**, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T, Sato T. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat Med* 2015; **21**: 256-262 [PMID: 25706875 DOI: 10.1038/nm.3802]

132 **Mandić AD**, Woting A, Jaenicke T, Sander A, Sabrowski W, Rolle-Kampcyk U, von Bergen M, Blaut M. Clostridium ramosum regulates enterochromaffin cell development and serotonin release. *Sci Rep* 2019; **9**: 1177 [PMID: 30718836 DOI: 10.1038/s41598-018-38018-z]

133 **Jattan J**, Rodia C, Li D, Diakhate A, Dong H, Bataille A, Shroyer NF, Kohan AB. Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine. *J Lipid Res* 2017; **58**: 853-865 [PMID: 28159868 DOI: 10.1194/jlr.M071340]

134 **Dekkers JF**, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM. A functional CFTR assay using primary cystic fibrosis intestinal organoids. *Nat Med* 2013; **19**: 939-945 [PMID: 23727931 DOI: 10.1038/nm.3201]

135 **Mora-Buch R**, Dotti I, Planell N, Calderón-Gómez E, Jung P, Masamunt MC, Llach J, Ricart E, Batlle E, Panés J, Salas A. Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. *Mucosal Immunol* 2016; **9**: 950-959 [PMID: 26530134 DOI: 10.1038/mi.2015.108]

136 **Moran CJ**, Klein C, Muise AM, Snapper SB. Very early-onset inflammatory bowel disease: gaining insight through focused discovery. *Inflamm Bowel Dis* 2015; **21**: 1166-1175 [PMID: 25895007 DOI: 10.1097/mib.0000000000000329]

137 **Bigorgne AE**, Farin HF, Lemoine R, Mahlaoui N, Lambert N, Gil M, Schulz A, Philippet P, Schlesser P, Abrahamsen TG, Oymar K, Davies EG, Ellingsen CL, Leteurtre E, Moreau-Massart B, Berrebi D, Bole-Feysot C, Nischke P, Brousse N, Fischer A, Clevers H, de Saint Basile G. TTC7A mutations disrupt intestinal epithelial apicobasal polarity. *J Clin Invest* 2014; **124**: 328-337 [PMID: 24292712 DOI: 10.1172/jci71471]

138 **Lehle AS**, Farin HF, Marquardt B, Michels BE, Magg T, Li Y, Liu Y, Ghalandary M, Lammens K, Hollizeck S, Rohlfs M, Hauck F, Conca R, Walz C, Weiss B, Lev A, Simon AJ, Groß O, Gaidt MM, Hornung V, Clevers H, Yazbeck N, Hanna-Wakim R, Shouval DS, Warner N, Somech R, Muise AM, Snapper SB, Bufler P, Koletzko S, Klein C, Kotlarz D. Intestinal Inflammation and Dysregulated Immunity in Patients With Inherited Caspase-8 Deficiency. *Gastroenterology* 2019; **156**: 275-278 [PMID: 30267714 DOI: 10.1053/j.gastro.2018.09.041]

139 **Farin HF**, Karthaus WR, Kujala P, Rakhshandehroo M, Schwank G, Vries RG, Kalkhoven E, Nieuwenhuis EE, Clevers H. Paneth cell extrusion and release of antimicrobial products is directly controlled by immune cell-derived IFN-γ. *J Exp Med* 2014; **211**: 1393-1405 [PMID: 24980747 DOI: 10.1084/jem.20130753]

140 **Park JH**, Kotani T, Konno T, Setiawan J, Kitamura Y, Imada S, Usui Y, Hatano N, Shinohara M, Saito Y, Murata Y, Matozaki T. Promotion of Intestinal Epithelial Cell Turnover by Commensal Bacteria: Role of Short-Chain Fatty Acids. *PLoS One* 2016; **11**: e0156334 [PMID: 27232601 DOI: 10.1371/journal.pone.0156334]

141 **Zhang YG**, Wu S, Xia Y, Sun J. Salmonella-infected crypt-derived intestinal organoid culture system for host-bacterial interactions. *Physiol Rep* 2014; **2**: [PMID: 25214524 DOI: 10.14814/phy2.12147]

142 **Barker N**, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007; **449**: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]

143 **Taniguchi K**, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. A gp130-Src-YAP module links inflammation to epithelial regeneration. *Nature* 2015; **519**: 57-62 [PMID: 25731159 DOI: 10.1038/nature14228]

144 **Seno H**, Miyoshi H, Brown SL, Geske MJ, Colonna M, Stappenbeck TS. Efficient colonic mucosal wound repair requires Trem2 signaling. *Proc Natl Acad Sci U S A* 2009; **106**: 256-261 [PMID: 19109436 DOI: 10.1073/pnas.0803343106]

145 **Miyoshi H**, VanDussen KL, Malvin NP, Ryu SH, Wang Y, Sonnek NM, Lai CW, Stappenbeck TS. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. *EMBO J* 2017; **36**: 5-24 [PMID: 27797821 DOI: 10.15252/embj.201694660]

146 **In J**, Foulke-Abel J, Zachos NC, Hansen AM, Kaper JB, Bernstein HD, Halushka M, Blutt S, Estes MK, Donowitz M, Kovbasnjuk O. Enterohemorrhagic <i>Escherichia coli</i> reduce mucus and intermicrovillar bridges in human stem cell-derived colonoids. *Cell Mol Gastroenterol Hepatol* 2016; **2**: 48-62.e3 [PMID: 26855967 DOI: 10.1016/j.jcmgh.2015.10.001]

147 **Ho NK**, Crandall I, Sherman PM. Identifying mechanisms by which Escherichia coli O157:H7 subverts interferon-γ mediated signal transducer and activator of transcription-1 activation. *PLoS One* 2012; **7**: e30145 [PMID: 22253910 DOI: 10.1371/journal.pone.0030145]

148 **Martinez-Medina M**, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. *World J Gastrointest Pathophysiol* 2014; **5**: 213-227 [PMID: 25133024 DOI: 10.4291/wjgp.v5.i3.213]

149 **Ossa JC**, Ho NK, Wine E, Leung N, Gray-Owen SD, Sherman PM. Adherent-invasive Escherichia coli blocks interferon-γ-induced signal transducer and activator of transcription (STAT)-1 in human intestinal epithelial cells. *Cell Microbiol* 2013; **15**: 446-457 [PMID: 23072252 DOI: 10.1111/cmi.12048]

150 **Lodes MJ**, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest* 2004; **113**: 1296-1306 [PMID: 15124021 DOI: 10.1172/jci20295]

151 **Sitaraman SV**, Klapproth JM, Moore DA 3rd, Landers C, Targan S, Williams IR, Gewirtz AT. Elevated flagellin-specific immunoglobulins in Crohn's disease. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G403-G406 [PMID: 15388489 DOI: 10.1152/ajpgi.00357.2004]

152 **Vijay-Kumar M**, Gewirtz AT. Role of flagellin in Crohn's disease: emblematic of the progress and enigmas in understanding inflammatory bowel disease. *Inflamm Bowel Dis* 2009; **15**: 789-795 [PMID: 19107795 DOI: 10.1002/ibd.20734]

153 **Eaves-Pyles TD**, Wong HR, Odoms K, Pyles RB. Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. *J Immunol* 2001; **167**: 7009-7016 [PMID: 11739521]

154 **Rieder F**, Bettenworth D, Imai J, Inagaki Y. Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology? *Inflamm Intest Dis* 2016; **1**: 41-49 [PMID: 29922656 DOI: 10.1159/000445135]

155 **Samuel G,** Gadeock S, Schultz M, Butt G. The Differential Response of Human Epithelial Derived Colonic Organoids to TLR Agonists. *FASEB J* 2017; **31**: 1049.6 [DOI: 10.1096/fasebj.31.1\_supplement.1049.6]

156 **Barrett KE**, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. *Annu Rev Physiol* 2000; **62**: 535-572 [PMID: 10845102 DOI: 10.1146/annurev.physiol.62.1.535]

157 **Rampton DS**, Sladen GE. Relationship between rectal mucosal prostaglandin production and water and electrolyte transport in ulcerative colitis. *Digestion* 1984; **30**: 13-22 [PMID: 6149163 DOI: 10.1159/000199086]

158 **Degagné E**, Grbic DM, Dupuis AA, Lavoie EG, Langlois C, Jain N, Weisman GA, Sévigny J, Gendron FP. P2Y2 receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells. *J Immunol* 2009; **183**: 4521-4529 [PMID: 19734210 DOI: 10.4049/jimmunol.0803977]

159 **Fujii S**, Suzuki K, Kawamoto A, Ishibashi F, Nakata T, Murano T, Ito G, Shimizu H, Mizutani T, Oshima S, Tsuchiya K, Nakamura T, Araki A, Ohtsuka K, Okamoto R, Watanabe M. PGE2 is a direct and robust mediator of anion/fluid secretion by human intestinal epithelial cells. *Sci Rep* 2016; **6**: 36795 [PMID: 27827428 DOI: 10.1038/srep36795]

160 **Hahn S**, Nam MO, Noh JH, Lee DH, Han HW, Kim DH, Hahm KB, Hong SP, Yoo JH, Yoo J. Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective. *Sci Rep* 2017; **7**: 2435 [PMID: 28550311 DOI: 10.1038/s41598-017-02190-5]

161 **Forkel M**, Mjösberg J. Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease. *Curr Allergy Asthma Rep* 2016; **16**: 73 [PMID: 27645534 DOI: 10.1007/s11882-016-0652-3]

162 **Westphalen CB**, Asfaha S, Hayakawa Y, Takemoto Y, Lukin DJ, Nuber AH, Brandtner A, Setlik W, Remotti H, Muley A, Chen X, May R, Houchen CW, Fox JG, Gershon MD, Quante M, Wang TC. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. *J Clin Invest* 2014; **124**: 1283-1295 [PMID: 24487592 DOI: 10.1172/jci73434]

163 **Noel G**, Baetz NW, Staab JF, Donowitz M, Kovbasnjuk O, Pasetti MF, Zachos NC. A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. *Sci Rep* 2017; **7**: 45270 [PMID: 28345602 DOI: 10.1038/srep45270]

164 **Peyrin-Biroulet L**, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, Gay J, Neut C, Colombel JF, Desreumaux P. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? *Gut* 2007; **56**: 577-583 [PMID: 16956921 DOI: 10.1136/gut.2005.082925]

165 **Mao R**, Kurada S, Gordon IO, Baker ME, Gandhi N, McDonald C, Coffey JC, Rieder F. The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn's Disease. *Inflamm Bowel Dis* 2019; **25**: 421-426 [PMID: 30346528 DOI: 10.1093/ibd/izy331]

166 **Takahashi Y**, Sato S, Kurashima Y, Lai CY, Otsu M, Hayashi M, Yamaguchi T, Kiyono H. Reciprocal Inflammatory Signaling Between Intestinal Epithelial Cells and Adipocytes in the Absence of Immune Cells. *EBioMedicine* 2017; **23**: 34-45 [PMID: 28789943 DOI: 10.1016/j.ebiom.2017.07.027]

167 **Holmberg FE**, Seidelin JB, Yin X, Mead BE, Tong Z, Li Y, Karp JM, Nielsen OH. Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. *EMBO Mol Med* 2017; **9**: 558-570 [PMID: 28283650 DOI: 10.15252/emmm.201607260]

168 **Noben M**, Vanhove W, Arnauts K, Santo Ramalho A, Van Assche G, Vermeire S, Verfaillie C, Ferrante M. Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology. *United European Gastroenterol J* 2017; **5**: 1073-1081 [PMID: 29238585 DOI: 10.1177/2050640617722903]

169 **Jalili-Firoozinezhad S**, Gazzaniga FS, Calamari EL, Camacho DM, Fadel CW, Bein A, Swenor B, Nestor B, Cronce MJ, Tovaglieri A, Levy O, Gregory KE, Breault DT, Cabral JMS, Kasper DL, Novak R, Ingber DE. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. *Nat Biomed Eng* 2019; **3**: 520-531 [PMID: 31086325 DOI: 10.1038/s41551-019-0397-0]

170 **Blander JM**. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. *FEBS J* 2016; **283**: 2720-2730 [PMID: 27250564 DOI: 10.1111/febs.13771]

171 **Noben M**, Verstockt B, de Bruyn M, Hendriks N, Van Assche G, Vermeire S, Verfaillie C, Ferrante M. Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease? *Gut* 2017; **66**: 2193-2195 [PMID: 28159838 DOI: 10.1136/gutjnl-2016-313667]

172 **Cramer JM**, Thompson T, Geskin A, LaFramboise W, Lagasse E. Distinct human stem cell populations in small and large intestine. *PLoS One* 2015; **10**: e0118792 [PMID: 25751518 DOI: 10.1371/journal.pone.0118792]

173 **Vermeire S**, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. *Lancet* 2017; **389**: 266-275 [PMID: 27988142 DOI: 10.1016/s0140-6736(16)32537-5]

174 **Mazur M**, Karczewski J, Lodyga M, Żaba R, Adamski Z. Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. *J Dermatolog Treat* 2015; **26**: 326-328 [PMID: 25424050 DOI: 10.3109/09546634.2014.991267]

175 **Gooderham M**, Papp K. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. *BioDrugs* 2015; **29**: 327-339 [PMID: 26481941 DOI: 10.1007/s40259-015-0144-3]

176 **Spadaccini M**, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. *Int J Mol Sci* 2017; **18**: [PMID: 28617319 DOI: 10.3390/ijms18061276]

177 **Thomson AW**, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. *Ther Drug Monit* 1995; **17**: 584-591 [PMID: 8588225]

178 **Usunier B**, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. *Stem Cells Int* 2014; **2014**: 340257 [PMID: 25132856 DOI: 10.1155/2014/340257]

179 **Pálmer HG**, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Muñoz A. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *J Cell Biol* 2001; **154**: 369-387 [PMID: 11470825]

180 **Watanabe Y**, Murata T, Amakawa M, Miyake Y, Handa T, Konishi K, Matsumura Y, Tanaka T, Takeuchi K. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. *Eur J Pharmacol* 2015; **754**: 179-189 [PMID: 25704618 DOI: 10.1016/j.ejphar.2015.02.021]

181 **Jiang GL**, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. *J Pharmacol Exp Ther* 2007; **320**: 22-28 [PMID: 17008451 DOI: 10.1124/jpet.106.111146]

182 **Otte JM**, Zdebik AE, Brand S, Chromik AM, Strauss S, Schmitz F, Steinstraesser L, Schmidt WE. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. *Regul Pept* 2009; **156**: 104-117 [PMID: 19328825 DOI: 10.1016/j.regpep.2009.03.009]

183 **Stremmel W**, Ehehalt R, Staffer S, Stoffels S, Mohr A, Karner M, Braun A. Mucosal protection by phosphatidylcholine. *Dig Dis* 2012; **30 Suppl 3**: 85-91 [PMID: 23295697 DOI: 10.1159/000342729]

184 **Schlee M**, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. *Infect Immun* 2007; **75**: 2399-2407 [PMID: 17283097 DOI: 10.1128/iai.01563-06]

**P-Reviewer:** Madnani MA, Marzaban R, Ray G, Sachar DB, Yang MS, Vradelis S **S-Editor:** Ma YJ **L-Editor:** A **E-Editor:** Wu YXJ

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** South Korea

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, b, b

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): E



 

**Figure 1 The normal intestinal epithelial barrier functions.** A: Physical barrier function; B: Biochemical barrier function; C: Innate immune barrier function. TFFs: Trefoil factors; ISCs: Intestinal stem cells; TJ: Tight junction; AJ: Adherens junction; MUC2: Mucin2; BEST2: Bestrophin2; TFF3: Trefoil factor3; REGIIIγ: Regenerating islet-derived protein IIIγ; UPR: Unfolded protein response; TLR: Toll like receptor; NLR: Nod like receptor; NF-kB: Nuclear factor kappa B; Th: T helper; Treg: Regulatory T cells; gp180: Glycoprotein-180; CD: cluster of differentiation; TCR: T cell receptor.

**Table 1 Enteroids/organoids retain the tissue specific transcriptional and epigenetic profiles**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Enteroids** **derived from** | **Distinct genes** | **Transcriptional/epigenetic** | **Culture period /passage number of enteroids** | **Human/mouse** | **Ref.** |
| Region-specific | Duodenum | *Gata4, Cybrd1, Slc40a1* | Increased mRNA  | 12 weeks | Mouse | [25] |
| Jejunum | *Gata4, Lct* |
| Ileum | *Slc10a2, Ostb* |
| Region- specific | Small bowel | *CHGA, ATOH1* | Increased mRNA | Not mentioned | Human fetus | [172] |
| Large bowel | *LGR5, MYC* |
| Region-specific | Terminal ileum | *SLC5A1, CLDN15* | Increased mRNA  | 3 months /11 passages | Human children and adults | [26] |
| *SATB2AS1* | Increased methylation |
| Sigmoid colon | *CFTR, SATB2* | Increased mRNA  |
| *IL6R, CLDN15* | Increased methylation |
| Disease-specific | Normal rectum | *GATA2* | Increased methylation | 3-5 passages | Human children | [26] |
| Gastric heterotopia in rectum | *SATB2AS1* |
| Disease-specific | Colon of non-IBD patients | *PLA2G2A, ZG16, CLCA1,**AQP8, MUC12* | Increased mRNA | 1 passage | Human | [14] |
| Colon of UC patients | *LYZ, ANXA10**CLDN18* |
| Disease-specific | Sigmoid colon of non-IBD patients | *LYZ* (low) | mRNA expression | Not mentioned | Human | [14] |
| Sigmoid colon of CD patients | *LYZ* (High) |
| Disease-specific | Healthy control | *GREB1, TMEM173* | Increased methylation | Not mentioned | Human children: Terminal ileum,sigmoid colon | [28] |
| CD patients | *PDE1B* |

*Gata4*: GATA binding protein 4, transcription factor specific to duodenum and jejunum; *Cybrd1*: Cytochrome b reductase 1 specific for iron uptake; *Slc40a1*: Solute carrier family 40 member 1, Fe2+ transporter ferroportin for iron uptake; *Lct*: Lactase-phlorizin hydrolase for dissacharide digestion; *Slc10a2*: Solute carrier family 10 member 2, apical sodium-dependent bile acid transporter; *Ostb*: Organic solute transporter beta for bile acid uptake; *CHGA*: Chromogranin A, a marker of enteroendocrine cells; *ATOH1*: Atonal BHLH Transcription Factor 1, key regulator of the Notch pathway; *LGR5*: Leucine rich repeat containing G protein-coupled receptor 5; *MYC*: MYC Proto-Oncogene, BHLH Transcription Factor; *SLC5A1*: Solute carrier family 5 member 1; *CLDN15*: Claudin 15; *SATB2AS1*: Special AT-rich sequence-binding protein 2 antisense 1; *CFTR*: Cystic fibrosis transmembrane conductance regulator; *SATB2*: Special AT-rich sequence-binding protein 2; *IL6R*: Interleukin-6 receptor; *GATA2*: GATA binding protein 2; *PLA2G2A*: Phospholipase A2 Group IIA, antibacterial enzyme; *ZG16*: Zymogen Granule Protein 16, mucus secreting cell marker; *CLCA1*: Chloride Channel Accessory 1, mucus secreting cell marker; *AQP8*: Aquaporin-8, water transporter; *MUC12*: Transmembrane mucin 12; *LYZ*: Lysozyme C; *ANXA10*: Annexin-10; *CLDN18*: Claudin 18; *GREB1*: Growth regulation by estrogen in breast cancer 1; *TMEM173*: Transmembrane protein 173; *PDE1B*: Phosphodiesterase 1B.

**Table 2 Current therapeutic approaches in inflammatory bowel diseases focused on immune cells**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Effects on immune cells** | **Drug type** | **Drug name/approach** | **Mechanism of action** | **Ref.** |
| Inhibits pro-inflammatory cytokine production | Classic anti-inflammatory drugs | 5-ASACorticosteroid | NF-kB inactivation | [77,78] |
| JAK inhibitors | Tofacitinib (JAK1/2/3) | Inhibits differentiation of Th1, Th2, and Th17 cells by inhibition of JAK/STAT pathway  | [90,91] |
| Filgotinib (JAK1) | [173] |
| ROR-γt inhibitor | GSK805 | Inhibits differentiation of Th17 cells but not ILC3s by inhibition of transcription factor ROR-γt | [92] |
| GATA3 specific DNAzyme (DNA antisense molecule) | Rectal delivery | Inhibits differentiation of Th2 cells by inhibition of transcription factor GATA3 expression | [93] |
| Anti-p40 subunit IL-12/IL-23 | Ustekinumab | Inhibits differentiation of Th1 and Th17 cells by neutralization of IL-12/IL-23 | [5,86] |
| PDE4 inhibitors | Apremilast, roflumilast | Increases intracellular cAMP which inhibits NF-kB (PDE4 degrades cAMP) | [174-176] |
| Induces apoptosis | Classic immunosuppressive agents | Azathioprine6-mercaptopurine | Metabolized purine analogue induces apoptosis by small GTPase RAC1 inactivation | [79] |
| Cyclosporine A | Activates caspase 8 signaling | [80,81] |
| Tacrolimus (FK506) | Inhibits calcineurin/NFAT pathway | [177] |
| Methotrexate | Cleavage of PARP but not caspase 3 activation | [82] |
| Anti-IL-6/IL-6R | PF-04236921 (anti-IL-6) | Inhibits IL-6/STAT3 signaling which mediates resistance against apoptosis | [87-89] |
| Tocilizumab (anti-IL-6R) |
| Blocks pro-inflammatory cytokines released from immune cells | Anti-TNF-α | Infliximab, adalimumab, golimumab, certolizumab pegol | Neutralizing antibody against TNF-α | [83] |
| Blocks trafficking or homing of immune cells toward inflamed gut | Gut specific anti-integrin | Vedolizumab (anti-α4β7)Etrolizumab (anti-β7) | Neutralizing antibody against integrin | [6-8,94,95] |
| Chemokine receptor (CCR9) inhibitor | Vercirnon (CCX282-B) | inhibits CCL25 (CCR9 ligand) directed chemotaxis | [96,97] |
| Anti-cell adhesion molecules | PF-00547659 | Neutralizing antibody against MAdCAM-1 (gut specific ligand for integrin α4β7) in vascular endothelial cells | [98,99] |
| Alicaforsen | ICAM-1 antisense oligonucleotide which inhibits ICAM-1 production in vascular endothelial cells | [100] |
| S1P1/S1P5 receptor agonist/functional antagonist | Ozanimod | Induces internalization and degradation of S1P receptor, and subsequently inhibit S1P/NF-kB/STAT3 pathway | [101-103] |
| Activates endogenous anti-inflammatory mechanisms | Anti-SMAD7 oligonucleotide | Mongersen | Activates anti-inflammatory TGFβ/SMAD3 signaling by degradation of SMAD7 mRNA | [104] |
| Mesenchymal stem cells | Transplantation | Directs T cell differentiation toward anti-inflammatory phenotype (Th2 cells, Treg) and inhibits T cell proliferation, cytokine production, and migration | [77,105,106,178] |
| Treg | Transplantation | Secretion of anti-inflammatory cytokines (TGFβ and IL-10) | [107] |

5-ASA: 5-Aminosalicylic acid; NF-kB: Nuclear factor kappa B; JAK: Janus kinase; STAT: Signal transducer and activator of transcription; ROR: RAR-related orphan receptor; Th: T helper; ILC3: Group3 innate lymphoid cells; GATA3: GATA binding protein 3; PDE4: Phosphodiesterase 4; cAMP: cyclic adenosine 3’5’-monophosphate; RAC1: Rac family small GTPase 1; NFAT: Nuclear factor of activated T cells; PARP: Poly (ADP-ribose) polymerase; CCR9: C-C motif chemokine receptor 9; MAdCAM-1: Mucosal vascular addressin cell adhesion molecule 1; ICAM-1: Intercellular adhesion molecule 1; S1P: Sphingosine-1-phosphate; SMAD: SMAD family member; Treg: Regulatory T cells.

**Table 3 Current therapeutic approaches in inflammatory bowel diseases focused on intestinal epithelial cells**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Effects on IECs** | **Drug type** | **Drug name/approach** | **Mechanism of action** | **Ref.** |
| Promotes physical barrier functions(by increasing proliferation and survival of IECs) | Anti-IL-22BP | Infliximab or adalimumab | Anti-TNF-α therapy may block the expression of IL-22BP, the endogenous inhibitor of IL-22(IL-22 is known to promote IEC proliferation *via* STAT3 activation in ISCs) | [108-111] |
| ER stress reducers | TUDCA, PBA | Reduce apoptosis by increasing protein folding capacity of ER | [112] |
| Human recombinant EGF | Enema | Promotes proliferation and reduces apoptosis of ISCs | [113,114] |
| Promotes physical barrier functions(by promoting expression and assembly of TJ proteins) | Inhibitor of para-cellular permeability | AT-1001 | Inhibits TJ disassembly by interfering with cytoskeletal rearrangement | [115] |
| Vitamin D | Calcitriol, vitamin D3 analogue | Induces expression of TJ proteins and E-cadherin | [117,179] |
| Sex hormone | Estradiol, diarylpropionitrile (estrogen receptor-β agonist) | Induces expression of TJ proteins (occludin, junctional adhesion molecule-A) | [118] |
| AMPK activator | Metformin | Induces expression and assembly of TJ proteins *via* AMPK dependent pathway | [119] |
| Promotes biochemical barrier functions (by promoting mucus secretion or production) | PGE2 receptor (subtype EP4) agonist | KAG-308, AGN205203 | Promotes mucus secretion and proliferation of goblet cells (Promotes proliferation and reduces apoptosis of IECs) | [120,123,145,180,181] |
| Short chain fatty acid | Butyrate | Stimulates mucin production by HDAC inhibitor activity | [121,124] |
| Recombinant anti-microbial peptide | Cathelicidin | Stimulates mucin production by MAPK dependent pathway | [122,182] |
| Phosphatidylcholine (PC) | LT-02 | Mucus component supplement for UC patients who have reduced PC in rectal mucus | [125,126,183] |
| Promotes biochemical barrier functions (by promoting anti-microbial peptide secretion or production) | TLR7 ligand | Imiquimod | Promotes anti-microbial peptide (defensin) production in IECs | [127] |
| Probiotics | *Escherichia coli* Nissle 1917 | Promotes anti-microbial peptide (defensin) production in IECs by NF-kB activation | [128,184] |
| Corrects innate immune barrier dysfunctions (by inhibiting the retention of T cells in inflamed site) | Gut specific anti-integrin | Etrolizumab (anti-β7) | Blocks the interaction between αEβ7 integrin on T cells with E-cadherin on IECs(Neutralizing antibody against integrin) | [129] |

IECs: Intestinal epithelial cells; IL-22BP: Interleukin-22 binding protein; STAT3: Signal transducer and activator of transcription 3; ISCs: Intestinal stem cells; ER: Endoplasmic reticulum; TUDCA: Tauroursodeoxycholate; PBA: 4-phenyl butyrate; EGF: Epidermal growth factor; TJ: Tight junction; AMPK: Adenosine monophosphate-activated protein kinase; PGE2: Prostaglandin E2; EP4: Prostaglandin E2 receptor 4; HDAC: Histone deacetylase; MAPK: Mitogen activated protein kinase; UC: Ulcerative colitis; TLR7: Toll-like receptor 7; NF-kB: Nuclear factor kappa B; IECs: Intestinal epithelial cells.